

FASCICULE DE BREVET D'INVENTION

21 Numéro de dépôt : 1201800495
PCT/EP2017/064665

22 Date de dépôt : 15/06/2017

30 Priorité(s) :

US n° 62/350919 du 16/06/2016

24 Délivré le : 12/12/2019

45 Publié le : 20/01/2020

73 Titulaire(s) :

Janssen Vaccines & Prevention B.V,
Archimedesweg 4,
2333 CN LEIDEN (NL)

72 Inventeur(s) :

NGUYEN Thierry-Thien (NL)
Mark BRUNER (NL)



74 Mandataire : Cabinet ÉKÉMÉ LYSAGHT SARL,
B.P. 6370, YAOUNDE (CM).

54 Titre : HIV vaccine formulation.

57 Abrégé :

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

Fig.1A Fig.1B



HIV Vaccine Formulation

BACKGROUND OF THE INVENTION

5 [0001] Human Immunodeficiency Virus (HIV) affects millions of people worldwide, and the prevention of HIV through an efficacious vaccine remains a very high priority, even in an era of widespread antiretroviral treatment. HIV-1 is the most common and pathogenic strain of the virus, with more than 90% of HIV/AIDS cases deriving from infection with HIV-1 group M. The M group is subdivided further into clades or subtypes. An efficacious vaccine
10 ideally would be capable of eliciting both potent cellular responses and broadly neutralizing antibodies capable of neutralizing HIV-1 strains from different clades.

[0002] The high genetic variability of HIV-1 makes the development of a HIV-1 vaccine an unprecedented challenge. In order to improve coverage of potential T-cell epitopes, and improve cellular responses, "mosaic" HIV-1 Gag, Pol and Env antigens, derived from HIV
15 Group Antigen (Gag), Polymerase (Pol), and Envelope (Env) proteins, were described by others and developed in an attempt to provide maximal coverage of potential T-cell epitopes (e.g., Barouch et al, *Nat Med* 2010, 16: 319-323). The mosaic antigens are similar in length and domain structure to wild-type, naturally occurring HIV-1 antigens.

[0003] Sequences encoding mosaic antigens have been cloned in vectors, for example,
20 such as recombinant adenovirus serotype 26 (rAd26), and these recombinant vectors have been used in vaccines to generate immune responses against HIV (see e.g. Barouch et al, *supra*; and WO 2010/059732). Viral vectors expressing such mosaic HIV antigens have proven to be effective in eliciting an immune response against HIV infection.

[0004] Another therapeutic strategy that has been explored for inducing immune
25 responses against HIV is the use of trimeric HIV envelope proteins as immunogens in vaccines, such as gp140. The native envelope spike on the surface of HIV is trimeric. Examples of trimeric envelope proteins include clade C gp140 protein, and a mosaic envelope trimer protein, such as those disclosed in WO 2014/042942 and WO 2014/107744.

[0010] Clade C gp140 protein has previously been described e.g. in WO 2010/042942
30 and in Nkolola et al. 2010, but there was no focus on any pharmaceutical formulation work in those disclosures. The protein was in phosphate-buffered saline (PBS) in some of the experiments in those disclosures. Mosaic gp140 has been described previously e.g. in WO 2014/107744 and in Nkolola et al 2014, but again there was no focus on any pharmaceutical

formulation work in those disclosures. The protein was in 25 mM Tris pH 7.5 and 150 mM NaCl in some of the experiments in those disclosures.

[0011] Trimeric HIV envelope proteins, such as gp140, are capable of inducing potent immune responses. Such envelope proteins can also be administered in combination with
5 other HIV antigens, such as mosaic antigens, to provide enhanced immunity against HIV. However, the stability of the HIV envelope proteins as trimers is not optimal under conditions typically used for clinical and commercial manufacturing. The trimeric HIV envelope proteins are susceptible to both chemical and physical degradation. Moreover, many different factors, such as the buffer formulation, can affect the stability of proteins, and
10 the effects are often unpredictable. For example, the use of HEPES buffer in protein formulations has been shown to result in generation of hydrogen peroxide when exposed to ambient light during the manufacturing process, which can impact the stability of the protein as well as other components in the formulation, such as surfactants. See, e.g., Baicu et al. *Cryobiology* (2002) 45(1) 33-48; Lepe-Zuniga et al. *J. Immunol. Methods* (1987) 103(1), 145;
15 and Zigler et al. *In Vitro Cell. Dev. Biol.* (1985) 21(5), 282-287. It is desirable to have an HIV vaccine gp140 formulation that would be suitable for stability of different variants of gp140 protein, such as Clade C or mosaic gp140, and preferably with Aluminum Phosphate adjuvant as a single vial drug product (rather than being entirely dependent upon pharmacy mixing immediately prior to delivery of the vaccine), and in addition would enable drug
20 product manufacturing meeting large late phase and commercial scale demands. It is generally unpredictable which combination of ingredients will result in a formulation that meets all these requirements.

[0012] Accordingly, there is a need in the art for improved formulations of HIV gp140 proteins with better stability under conditions used for clinical and commercial
25 manufacturing in order to realize the full therapeutic potential of such trimeric envelope proteins. These formulations should also be compatible for use with additional HIV antigen(s), including vectors expressing HIV antigen(s), and/or adjuvants.

BRIEF SUMMARY OF THE INVENTION

[0005] The invention relates to immunogenic compositions of HIV gp140 proteins that
30 have improved stability. The immunogenic compositions of the invention can be stored under refrigerated conditions for extended periods of time, and are more optimal for use in clinical and commercial manufacturing. The immunogenic compositions of the invention can also include an adjuvant. The invention also relates to methods of preparing the

immunogenic compositions, and methods of using the immunogenic compositions to induce an immune response against HIV.

[0006] In one general aspect, the invention relates to an immunogenic composition comprising, relative to the total volume of the composition:

- 5
- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
 - b. 2% to 15% (w/v) sorbitol;
 - c. 0.01 to 0.05% (w/v) polysorbate 20; and
 - d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0.

[0010] Preferably, an immunogenic composition according to an embodiment of the invention comprises a stabilized trimeric HIV gp140 protein, such as an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

[0011] In particular embodiments of the invention, the immunogenic composition comprises 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein.

[0012] In particular embodiments, an immunogenic composition according to an embodiment of the invention comprises 5% (w/v) to 12% (w/v) sorbitol.

[0013] In particular embodiments, the immunogenic composition comprises 0.02% (w/v) polysorbate 20.

[0014] In particular embodiments, the immunogenic composition comprises 10 mM histidine buffer at a pH of 6.5.

20 [0015] According to embodiments of the invention, the immunogenic composition can further comprise an adjuvant, such as aluminum phosphate adjuvant. In certain of such embodiments, aluminum phosphate may be present in the composition at a concentration of 0.7-5.0 mg/mL, e.g. 0.8-4.0 mg/mL, e.g. 0.85 mg/mL, 1 mg/mL, 1.5 mg/mL, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL, 3.5 mg/mL, 3.84 mg/mL, 4.0 mg/mL. In certain embodiments,

25 aluminum phosphate is present in the immunogenic compositions at a concentration of 0.85 mg/mL. In certain embodiments, aluminum phosphate is present in the immunogenic compositions at a concentration of 3.84 mg/mL.

[0016] In a preferred embodiment of the invention, an immunogenic composition comprises, relative to a total volume of the composition,

- 30
- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2
 - b. 5% to 12% (w/v) sorbitol;
 - c. 0.02% (w/v) polysorbate 20;
 - d. 10 mM histidine buffer at a pH of 6.5; and

- e. aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL.

[0017] In another general aspect, the invention relates to a method of preparing an immunogenic composition comprising admixing:

- 5 a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
- b. 2% to 15% (w/v) sorbitol;
- c. 0.01 to 0.05% polysorbate 20; and
- d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0;

to thereby obtain the immunogenic composition.

10 [0018] In certain embodiments, the immunogenic composition of the invention comprises aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL, and is stable upon storage at a temperature of 2-8°C, for at least one month, preferably at least 2, 3, 4, 5, 6 months, more preferably at least 7, 8, 9, 10, 11, 12 months, still more preferably at least 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months, most preferably at least 25, 26, 27, 28, 29, 15 30, 31, 32, 33, 34, 35, 36 months or longer, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months. In certain embodiments, the immunogenic composition of the invention comprises aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL, and is stable at a temperature of 25°C for at least 6 months, e.g. 6-12 months, or 6-24 months. In certain 20 embodiments, the immunogenic composition of the invention comprises aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL, and is stable at a temperature of 40°C for at least 1 week, e.g. 1-12 weeks, e.g. at least 2 weeks, 3 weeks, 4 weeks, 1 month, e.g. 1-2 months, 1-3 months, or 3-6 months.

[0019] And in another general aspect, the invention relates to a method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject in need 25 thereof, comprising administering to the subject an effective amount of an immunogenic composition of the invention.

[0020] In a particular embodiment, a method of inducing an immune response against an HIV comprises administering to a subject in need thereof an immunogenic composition comprising, relative to the total volume of the composition,

- 30 a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;
- b. 5% to 12% (w/v) sorbitol;
- c. 0.02% polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5; and
- 35 e. aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL.

[0021] In certain embodiments of the invention, a method of inducing an immune response against an HIV further comprises administering to the subject an effective amount of a second immunogenic composition comprising or encoding one or more additional HIV antigens, such as those comprising or encoding an amino acid sequence of SEQ ID NOs: 3-12. Preferably, the method comprises administering one or more vectors, preferably adenovirus 26 vectors, encoding one or more HIV antigens, such as those comprising an amino acid sequence of SEQ ID NOs: 3-12. Methods of inducing an immune response against an HIV can also comprise administering one or more MVA vectors encoding one or more HIV antigens, such as those comprising an amino acid sequence of SEQ ID NOs: 3-12. The one or more additional HIV antigens can also comprise SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575). In one embodiment, the antigen comprising SEQ ID NO: 11 comprises SEQ ID NO: 12.

[0022] In another general aspect, the invention relates to a method for preparing a long-term, storage stable immunogenic composition that comprises HIV gp140 protein, the method comprising:

- (i) admixing the following components to create an immunogenic composition comprising these components in amounts relative to the total volume of the composition:
- (a) 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
 - (b) 2% to 15% (w/v) sorbitol;
 - (c) 0.01 to 0.05% (w/v) polysorbate 20; and
 - (d) 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0,
 - (e) water,
 - (f) aluminum phosphate adjuvant, preferably at a concentration of 0.7-4.0 mg/mL;

and

- (ii) storing the composition at 2-8°C for at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months.

BRIEF DESCRIPTION OF THE FIGURES

[0023] The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. It should be understood that the invention is not limited to the precise embodiments shown in the drawings.

[0024] In the figures:

[0025] Figs. 1A and 1B show the results of SolvoVPE analysis of HIV gp140 protein formulations prepared with acetate buffer, phosphate buffer, and histidine buffer, and dynamic light scattering (DLS) analysis of HIV gp140 protein formulations prepared with sorbitol and sucrose; in particular:

Fig. 1A shows the results of the SolvoVPE analysis; the change in absorbance at 350 nm (turbidity) is plotted against the change in absorbance at 280 nm (concentration); data points indicate the change between samples analyzed at time 0 (T_0) and after stressing the samples at 40 °C for 24 hours (T_{24}); SolvoVPE analysis was performed as described in Example 1;

Fig. 1B shows the results of the DLS analysis; the change in radius (R_h) from time 0 (T_0) at 20°C to time 7 days ($T_{7 \text{ days}}$) at 70°C is plotted by sugar (sucrose vs. sorbitol); DLS analysis was performed as described in Example 1;

[0026] Figs. 2A-2F show the results of high-performance size exclusion chromatography (HP-SEC) analysis of HIV gp140 formulations as described in Example 2; the relative amount of hexamer, trimer and high/low molecular weight species of HIV clade C gp140 protein was determined by HP-SEC of samples analyzed at time 0 (T_0) and after stressing the samples at 40°C for 24 hours (T_{24}); “Tri +Hex” refers to the relative amount of trimer and hexamer species of HIV clade C gp140 protein; “LMW” refers to low molecular weight species, e.g., cleavage or degradation products, in particular:

Fig. 2A shows the relative amount (%) of hexamer and trimer species of HIV clade C gp140 protein in T_0 samples at different protein concentrations (0.2 mg/mL and 1.0 mg/mL);

Fig. 2B shows the relative amount (%) of hexamer and trimer species of HIV gp140 clade C protein in T_0 samples at different concentrations of surfactant (0.02% and 0.1%); the data shown is a combination of data collected from samples containing PS20 and samples containing PS80;

Fig. 2C shows the relative amount (%) of hexamer and trimer species of HIV clade C gp140 protein in T_{24} samples at different protein concentrations (0.2 mg/mL and 1.0 mg/mL);

Fig. 2D shows the relative amount (%) of hexamer and trimer species of HIV gp140 clade C protein in T₂₄ samples at different concentrations of surfactant (0.02% and 0.1%); the data shown is a combination of data collected from samples containing PS20 and samples containing PS80;

5 Fig. 2E shows the relative amount (%) of low molecular weight species of HIV clade C gp140 protein based on surfactant type (PS20 versus PS80) in T₀ samples;

Fig. 2F shows the relative amount (%) of low molecular weight species of HIV gp140 clade C protein in T₂₄ samples at different concentrations of surfactant;

[0027] Figs. 3A and 3B show the results of stability studies of HIV gp140 protein
10 formulations according to embodiments of the invention; HIV mosaic gp140 protein formulations were subjected to multiple freeze-thaw cycles as described in Example 3;

Fig. 3A shows the protein concentration after one, three, and five freeze-thaw cycles as determined by measuring the absorbance at 280 nm; and

15 Fig. 3B shows the turbidity of the tested formulations after one, three, and five freeze-thaw cycles as determined by measuring the absorbance at 350 nm; and

[0028] Figs. 4A-4C show the results of stability studies of HIV clade C gp140 protein formulations; HIV clade C gp140 protein formulations were stored at 25°C and 60% relative humidity (RH), and 40°C and 75% RH, both with and without aluminum phosphate adjuvant, and then tested using a reduced SDS analytical method as described in Example 4;

20 Fig. 4A shows the relative protein concentration (%) of HIV clade C gp140 formulations stored at 25°C and 60% RH without any aluminum phosphate adjuvant;

Fig. 4B shows the relative protein concentration (%) of HIV clade C gp140 formulations stored at 40°C and 75% RH without any aluminum phosphate adjuvant;

25 Fig. 4C shows the relative protein concentration (%) of HIV clade C gp140 formulations stored at 25°C and 60% RH with aluminum phosphate adjuvant; and

Fig. 4D shows the relative protein concentration (%) of HIV clade C gp140 formulations stored at 40°C and 75% RH with aluminum phosphate adjuvant.

DETAILED DESCRIPTION OF THE INVENTION

30 [0029] Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the

invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed.

[0030] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set forth in the specification. All patents, published patent applications and publications cited herein are incorporated by reference as if set forth fully herein. It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.

[0031] Unless otherwise stated, any numerical values, such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term “about.” Thus, a numerical value typically includes $\pm 10\%$ of the recited value. For example, a concentration of 1 mg/mL includes 0.9 mg/mL to 1.1 mg/mL. Likewise, a concentration range of 1% to 10% (w/v) includes 0.9% (w/v) to 11% (w/v). As used herein, the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise.

[0032] As used herein, “subject” means any animal, preferably a mammal, most preferably a human, to whom will be or has been administered an immunogenic composition according to embodiments of the invention. The term “mammal” as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., more preferably a human.

[0033] The invention generally relates to immunogenic compositions comprising HIV gp140 protein and optionally adjuvant, methods of preparing and storing such compositions, and methods of inducing an immune response against HIV in a subject with the immunogenic compositions, alone or in combination with one or more additional HIV antigens, which are preferably expressed by one or more vectors.

[0034] HIV Antigens

[0035] Human immunodeficiency virus (HIV) is a member of the genus *Lentivirinae*, which is part of the family of *Retroviridae*. Two species of HIV infect humans: HIV-1 and HIV-2. HIV-1 is the most common strain of HIV virus, and is known to be more pathogenic than HIV-2. As used herein, the terms “human immunodeficiency virus” and “HIV” refer to, but are not limited to, HIV-1 and HIV-2.

[0036] HIV is categorized into multiple clades with a high degree of genetic divergence. As used herein, the term “HIV clade” or “HIV subtype” refers to related human

immunodeficiency viruses classified according to their degree of genetic similarity. There are currently three groups of HIV-1 isolates: M, N, and O. Group M (major strains) consists of at least ten clades, A through J. Group O (outer strains) can consist of a similar number of clades. Group N is a new HIV-1 isolate that has not been categorized in either group M or O.

[0037] As used herein, the terms “HIV antigen,” “HIV antigenic protein,” “HIV antigenic polypeptide,” and “HIV immunogen” refer to a polypeptide capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against HIV in a subject. The HIV antigen can be a protein of HIV, a fragment or epitope thereof, or a combination of multiple HIV proteins or portions thereof, that can induce an immune response or produce an immunity, e.g., protective immunity, against HIV in a subject.

[0038] Preferably, an antigen is capable of raising in a host a protective immune response, e.g., inducing an immune response against a viral disease or infection, and/or producing an immunity in (i.e., vaccinating) a subject against a viral disease or infection, that protects the subject against the viral disease or infection. For example, the antigen can comprise a protein or fragments thereof from HIV, such as the HIV *gag*, *pol* and *env* gene products.

[0039] An HIV antigen can be any HIV-1 or HIV-2 antigen or fragment thereof.

Examples of HIV antigens include, but are not limited to *gag*, *pol*, and *env* gene products, which encode structural proteins and essential enzymes. *Gag*, *pol*, and *env* gene products are synthesized as polyproteins, which are further processed into multiple other protein products. The primary protein product of the *gag* gene is the viral structural protein Gag polyprotein, which is further processed into MA, CA, SP1, NC, SP2, and P6 protein products. The *pol* gene encodes viral enzymes (Pol, polymerase), and the primary protein product is further processed into RT, RNase H, IN, and PR protein products. The *env* gene encodes structural proteins, specifically glycoproteins of the virion envelope. The primary protein product of the *env* gene is gp160, which is further processed into gp120 and gp41.

[0040] In certain embodiments, the HIV antigen comprises an HIV Gag, Env, or Pol antigen, or any antigenic portion or epitope or combination thereof, preferably an HIV-1 Gag, Env, or Pol antigen or any antigenic portion or epitope or combination thereof.

[0041] HIV antigens can also be mosaic HIV antigens. As used herein, “mosaic antigen” refers to a recombinant protein assembled from fragments of natural sequences. Mosaic antigens resemble natural antigens, but are optimized to maximize the coverage of potential

T-cell epitopes found in the natural sequences, which improves the breadth and coverage of the immune response. Mosaic HIV antigens for use with the invention are preferably mosaic HIV-1 Gag, Pol, and/or Env antigens. Mosaic HIV Gag, Pol, and/or Env antigens are mosaic antigens comprising multiple epitopes derived from one or more of the Gag, Pol, and/or Env polyprotein sequences of HIV. For example, a mosaic GagPol antigen comprises a mosaic Gag sequence and a mosaic Pol sequence.

[0042] Examples of mosaic HIV Gag, Pol, and/or Env antigens that can be used in the invention include those described in, e.g., US20120076812; Barouch et al., *Nat Med* 2010, 16:319-323; and Barouch et al., *Cell* 155:1-9, 2013, all of which are incorporated herein by reference in their entirety. Preferably, mosaic HIV Gag, Pol, and/or Env antigens for use with the invention include, but are not limited to, mos1Env (SEQ ID NO: 3), mos2Env (SEQ ID NO: 4), mos1Pol (SEQ ID NO: 5), mos2Pol (SEQ ID NO: 6), mos1Gag (SEQ ID NO: 7), mos2Gag (SEQ ID NO: 8), and combinations thereof, for example mos1GagPol (SEQ ID NO: 9) and mos2GagPol (SEQ ID NO: 10). Other examples of mosaic HIV antigens include synthetic HIV Env proteins, which are non-naturally occurring HIV envelope proteins optimized to induce an immune response or provide an immunity against one or more naturally occurring HIV strains, such as that comprising SEQ ID NO: 11, or SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575), or in preferred embodiments, the antigen comprising SEQ ID NO: 11 comprises the amino acid sequence of SEQ ID NO: 12, all as described in PCT/EP2016/081159 (filed on 15 December 2016 in the name of Janssen Vaccines & Prevention B.V.), which is herein incorporated by reference in its entirety.

[0043] HIV gp140 Protein

[0044] As used herein, the term "HIV gp140 protein" refers to an uncleaved ectodomain of trimeric gp160 envelope protein, i.e., (gp160)₃. Embodiments of the invention relate to improved formulations of HIV gp140, preferably a trimer and/or hexamer of the gp140 subunits bound to the ectodomain of the gp41 subunits lacking the gp41 transmembrane and cytoplasmic segments. The HIV *env* gene encodes the precursor protein gp160, which is proteolytically cleaved into the two mature envelope glycoproteins gp120 and gp41. First, gp160 trimerizes to (gp160)₃ and then undergoes cleavage into the two noncovalently associated proteins gp120 and gp41 via a cleavage reaction mediated by a host cell protease,

furin, at a sequence highly conserved in retroviral envelope glycoprotein precursors. Viral entry is subsequently mediated by a trimer of gp120/gp41 heterodimers. Gp120 is the receptor binding fragment, and binds to the CD4 receptor on a target cell that has such a receptor, such as, e.g., a T-helper cell. Gp41, which is non-covalently bound to gp120, is the fusion fragment and provides the second step by which HIV enters the cell. Gp41 is originally buried within the viral envelope, but when gp120 binds to a CD4 receptor, gp120 changes its conformation causing gp41 to become exposed, where it can assist in fusion with the host cell. HIV gp140 protein has been used as a surrogate for the native state of the cleaved, viral spike.

5 [0045] Expression of gp140 proteins has been described in several publications (e.g. Zhang et al., 2001; Sanders et al., 2002; Harris et al., 2011), and the protein can nowadays also be ordered from service providers, in different variants e.g. based on different HIV strains. A gp140 protein according to the invention can have a cleavage site mutation so that the gp120 domain and gp41 ectodomain are covalently linked, or alternatively the gp120 domain and gp41 ectodomain can be non-covalently linked (e.g. by a disulphur bridge as for instance in SOSIP variants). Gp140 proteins have been used in various vaccination experiments (e.g. Nkolola et al., 2010, 2014; Kovacs et al., 2012; Barouch et al., 2015; Sanders et al., 2015).

10 [0046] According to embodiments of the invention, the HIV gp140 protein can be a homotrimer (e.g., trimers comprising three identical polypeptide units), or a heterotrimer (e.g., trimers comprising three polypeptides that are not all identical). The HIV gp140 protein can also be a hexamer. Both trimer species and hexamer species of HIV gp140 protein have immunogenicity against HIV, or can induce immune responses against HIV *in vivo*. Preferably, the HIV gp140 protein is a trimer, and more preferably a homotrimer. An HIV gp140 protein can be a naturally occurring sequence, e.g., a sequence isolated from any HIV clade, such as clade A, clade B, clade C, etc., or a mosaic gp140 protein. A “mosaic gp140 protein” contains multiple epitopes derived from one or more gp140 sequences of one or more HIV clades.

15 [0047] Preferably, an HIV gp140 protein is a stabilized trimeric gp140 protein. A “stabilized trimeric gp140 protein” is a gp140 protein that can have or can be modified to include a polypeptide sequence, such as a trimerization domain, that increases the stability of the trimeric structure, or it can be a gp140 protein that is modified to contain mutations (as compared to natural gp140 sequences) that stabilize a trimeric structure, such as SOSIP and/or other mutations. Examples of trimerization domains include, but are not limited to,

the T4-fibritin “foldon” trimerization domain, e.g., that having the amino acid sequence of GSGGYIPEAPRDGQAYVRKDGWVLLSTFL (SEQ ID NO: 13); the coiled-coil trimerization domain derived from GCN4, e.g., that having the amino acid sequence of MKQIEDKIEEILSKIYHIENEIARIKKLIGEV (SEQ ID NO: 14); and the catalytic subunit of *E. coli* aspartate transcarbamoylase as a trimer tag. Such trimerization domains can be used to support stable trimer formation (see e.g. WO 2010/042942, Nkolola et al. 2010, WO 2014/107744, and Nkolola et al. 2014, for stabilized trimers of gp140 proteins). A stabilized trimeric gp140 protein for use in the invention can also include cleavage site mutations to enhance stability, e.g., in the furin cleavage sites, and/or so-called SOSIP mutations (see, e.g. Sanders et al., 2002, 2015). A stabilized trimeric gp140 protein can be derived from a gp140 protein isolated from any HIV clade, e.g., clade A, clade B, clade C, etc. A stabilized trimeric gp140 protein can also be a stabilized mosaic gp140 protein.

[0048] Exemplary HIV gp140 proteins that can be used in the invention include HIV clade C gp140 protein (SEQ ID NO: 1), HIV mosaic gp140 protein (SEQ ID NO: 2), and combinations thereof. Both the HIV clade C gp140 protein (SEQ ID NO: 1) and HIV mosaic gp140 protein (SEQ ID NO: 2) are stabilized trimeric gp140 proteins comprising a T4-fibritin “foldon” trimerization domain.

[0049] Immunogenic Compositions

[0050] In a first aspect, the invention relates to an immunogenic composition comprising an HIV gp140 protein. An “immunogenic composition” as used herein refers to a composition capable of inducing an immune response in a subject who has been or will be administered the composition. An immunogenic composition can be a vaccine. A “vaccine” refers to a composition that can provide protective immunity or a protective immune response to a subject, or that can be used to vaccinate a subject. According to embodiments of the invention, any HIV gp140 protein known in the art in view of the present disclosure can be used in an immunogenic composition of the invention. An immunogenic composition can comprise one or more HIV gp140 proteins, such as one, two, or three HIV gp140 proteins.

[0051] Preferably, the immunogenic composition of the invention comprises a stabilized trimeric gp140 protein. In one preferred embodiment, an HIV gp140 protein is an HIV clade C gp140 protein, such as that comprising the amino acid sequence of SEQ ID NO: 1. In another preferred embodiment, an HIV gp140 protein is a HIV mosaic gp140 protein, such as that comprising the amino acid sequence of SEQ ID NO: 2.

[0052] In other embodiments, an immunogenic composition comprises both an HIV clade C gp140 protein and an HIV mosaic gp140 protein, such as those comprising SEQ ID NO: 1

and SEQ ID NO: 2. For example, an immunogenic composition can comprise a mixture of an HIV clade C gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 and an HIV mosaic gp140 protein comprising the amino acid sequence of SEQ ID NO: 2, e.g., in a 1:1 ratio.

5 [0053] The immunogenic compositions of the invention also comprise water, preferably water for injection. It is added to the composition in sufficient quantity (q.s.), depending on the volume of the composition being prepared.

[0054] According to embodiments of the invention, an immunogenic composition comprises 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein, such as 0.05 mg/mL, 0.1
10 mg/mL, 0.2 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, or 5 mg/mL. In particular embodiments of the invention, an immunogenic composition comprises 0.2 mg/mL or 1 mg/mL of an HIV gp140 protein, such as those comprising SEQ ID NO: 1 or SEQ ID NO: 2. In other particular embodiments of the invention, an immunogenic composition comprises a 0.05 mg/mL to 5 mg/mL of a mixture of HIV gp140 proteins, such as those
15 comprising SEQ ID NO: 1 and SEQ ID NO: 2, e.g., in a 1:1 ratio.

[0055] Immunogenic compositions of the invention further comprise sorbitol (sugar), polysorbate 20 (surfactant), and histidine buffer. The inventors surprisingly discovered that the stability of the HIV gp140 protein in a composition comprising histidine had improved stability as compared to that in compositions comprising other amino acids. The inventors
20 also surprisingly discovered that inclusion of polysorbate 20 in the composition further improved the stability of the HIV gp140 protein in the composition. Typically, buffers used for protein formulations contain a combination of acetate and sorbitol, or a combination of histidine and sucrose (see e.g., Uchiyama, *Biochimica Biophysica Acta* (2014) 1844, 2041-2052). Histidine and sorbitol are not usually used in combination in a buffer for protein
25 formulations. To the best of the knowledge of the inventors, the combination of histidine and sorbitol with polysorbate 20 (surfactant) has not been used in any commercial protein drug formulations. Therefore, it was surprising to see that the combination of histidine and sorbitol improved the stability of the HIV gp140 protein.

[0056] According to embodiments of the invention, the concentration of sorbitol can be
30 in a range of 2% to 15% (w/v), such as 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% (w/v). In one preferred embodiment, the concentration of sorbitol is 5% (w/v). In another preferred embodiment, the concentration of sorbitol is 12% (w/v).

[0057] According to embodiments of the invention, the concentration of polysorbate 20 can be in a range of 0.01% to 0.05% (w/v), such as 0.01%, 0.02%, 0.03%, 0.04%, or 0.05% (w/v). In one preferred embodiment, the concentration of polysorbate 20 is 0.02% (w/v).

[0058] According to embodiments of the invention, the concentration of histidine buffer is in a range of 5 mM to 20 mM, such as 5 mM, 10 mM, 15 mM or 20 mM, and is preferably 10 mM. The pH of the histidine buffer is in a range of 5.5 to 7.0, such as 5.5, 6.0, 6.5, or 7.0, and is preferably 6.5. In one preferred embodiment, the concentration of the histidine buffer is 10 mM and the pH of the histidine buffer is 6.5. Any pH value described herein, is to be understood as being modified in all instances by the term "about," which, when used with reference to a pH value includes ± 0.5 of the recited pH value. Unless specified otherwise, all pH values refer to the pH of the histidine buffer itself that is included in an immunogenic composition of the invention.

[0059] In certain embodiments of the invention, an immunogenic composition further comprises an adjuvant. The terms "adjuvant" and "immune stimulant" are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system, or enhance an immune response. For example, an adjuvant can be used to enhance an immune response to an HIV gp140 protein and/or an immunogenic composition of the invention when administered alone or further in combination with one or more adenovirus vectors encoding one or more HIV antigens. Adjuvants suitable for use with the invention should be ones that are potentially safe, well tolerated and effective in people, such as, for instance QS-21, Iscomatrix, Detox-PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL- 1005, GERBU, TERamide, PSC97B, Adjuver, PG-026, GSK-I, GcMAF, B-alethine, MPC-026, Adjuvax, CpG ODN, Betafectin, aluminum salts (e.g. aluminum hydroxide, and/or aluminum phosphate; an example of an aluminum phosphate adjuvant is AdjuPhos, a sterilized aluminum phosphate wet gel suspension), Adjuplex, and MF59. Preferably, the adjuvant is an aluminum phosphate adjuvant.

[0060] According to embodiments of the invention, an aluminum phosphate adjuvant can be included in an immunogenic composition at concentrations of between about 0.7 and 5.0 mg/mL, for instance 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, or 1 mg/ml, e.g. at a fixed concentration of 0.85 mg/mL, or for instance 1.5, 2.0, 2.5, 3.0, 3.5, 3.6, 3.7, 3.8, 3.85, 3.9, 3.95, 4.0, 4.5, or 5.0 mg/mL, e.g. at a fixed concentration of 3.84 mg/mL. One goal of the invention was to provide long-term stable formulations with aluminum phosphate adjuvant present together with the gp140 protein immunogen. It was surprisingly found that the liquid formulations of the invention that comprise HIV gp140, histidine buffer, sorbitol, and polysorbate 20, are

stable for at least 6 months at 2-8°C. These formulations were also found to be stable for at least 6 months at elevated temperatures of 25°C. In addition, these formulations were even found to be stable for at least 2 weeks, 1 month, or even up to 3 months at 40°C, as measured by reduced SDS PAGE.

- 5 [0061] In an exemplary embodiment of the invention, an immunogenic composition comprises, relative to the total volume of the composition:
- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;
 - b. 5% to 12% (w/v) sorbitol;
 - 10 c. 0.02% (w/v) polysorbate 20;
 - d. 10 mM histidine buffer at a pH of 6.5; and
 - e. 0.7 to 4.0 mg/mL (e.g. 0.85 mg/mL or 3.84 mg/mL) aluminum phosphate adjuvant.

[0062] Immunogenic compositions of the invention can be formulated in any matter
15 suitable for administration to a subject to facilitate administration and improve efficacy, including, but not limited to, oral (enteral) administration and parenteral injections. The parenteral injections for instance can include subcutaneous injection, intramuscular injection, or intradermal injection. Immunogenic compositions of the invention can also be formulated for other routes of administration, e.g. transmucosal, rectal, sublingual administration, oral, or
20 intranasal. Preferably, an immunogenic composition is formulated for intramuscular injection.

[0063] Immunogenic compositions of the invention are advantageous in that the HIV gp140 protein can be stably stored in liquid form at refrigerated temperature, for instance 2°C to 8°C, for extended periods of time, such as about 2 years. In certain embodiments, the
25 immunogenic compositions include an adjuvant, for instance aluminum phosphate adjuvant. The immunogenic compositions containing adjuvant are also compatible with storage in liquid form under refrigerated conditions for extended periods of time. The immunogenic compositions of the invention are also compatible with storage in lyophilized form. However, the compositions of the invention are thus preferably liquid formulations, meaning that they
30 are in liquid form at the preferred storage temperature, i.e. at 2-8°C. Typically the liquid formulations or compositions according to the invention are aqueous suspensions, meaning that not all protein and/or particulate material such as aluminum phosphate may be entirely dissolved. In such cases it is advised to mix the composition before use. It is preferred to

store the compositions of the invention that comprise aluminum phosphate adjuvant above the freezing point of water, most preferably at 2-8°C, e.g. e.g. 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, or 8°C. Advantages are that no resource-intensive and costly lyophilization and associated re-dissolving before use is needed, no bed-side mixing and separate storage of the aluminum phosphate adjuvant is needed but rather the formulations can be stored 'ready-for-use'. In addition, storage at refrigerated but not frozen conditions makes that the compositions can be used more easily in resource-limited settings e.g. where no freezing capacity is available. Moreover, the observed maintained stability at elevated temperatures (e.g. 25°C, and even 40°C) of the compositions of the invention indicates that inadvertent temperature excursions, e.g. when temporarily the composition is exposed to room temperature even in warm climates, should not immediately be detrimental to the vaccine composition of the invention.

[0064] The compositions of the invention, surprisingly including the ones comprising aluminum phosphate, are stable upon storage at a temperature of 2-8°C for at least one day, one week, two weeks, one month, preferably at least 2, 3, 4, 5, 6 months. More preferably these compositions are stable under these conditions for at least 7, 8, 9, 10, 11, 12 months, still more preferably at least 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 months, most preferably at least 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months or longer, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months. The invention in certain embodiments thus provides compositions according to the invention, which are stable when stored at 2-8°C for at least one month, at least three months, at least 6 months. Preferably such compositions are stable for at least 12 months, at least 18 months, at least 24 months, at least 30 months, at least 36 months. In certain embodiments, the invention provides using the immunogenic compositions of the invention for vaccinating a subject, preferably a human subject, after the immunogenic compositions have been stored at 2-8°C for at least one day, at least one week, at least two weeks, at least three weeks, at least one month, at least two months, at least three months, at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months.

[0065] For the purpose of the present invention, an immunogenic composition that comprises HIV gp140 protein and that after having been stored for at least one week, preferably at least one month, at a given temperature does not show more than 25%, preferably not more than 10%, of degradation of said gp140 protein on a reduced SDS PAGE gel, is considered a long-term storage stable immunogenic composition at said temperature. An immunogenic composition that comprises HIV gp140 protein is considered "stable" according to the present invention under certain conditions (e.g. 2-8°C) for a specified time

(e.g. 6 months), if under these conditions after said specified time said gp140 protein does not show more than 25%, preferably less than 20%, preferably less than 15%, preferably less than 10%, most preferably less than 5%, of degradation (compared to initial measurement at $t=0$) on a reduced SDS PAGE gel. Degradation is visible as additional bands below the gp140 band of desired molecular weight. Alternative assays such as ELISA can also be used to measure stability, and in certain embodiments, a composition that is stable as defined above, also does not show more than 50%, preferably less than 25%, degradation (reduction as compared to initial signal at $t=0$) in an ELISA assay.

[0066] Methods of Preparing an Immunogenic Composition

10 [0067] The invention also relates to a method of preparing an immunogenic composition of the invention. According to embodiments of the invention, a method of preparing an immunogenic composition comprises admixing an HIV gp140 protein, sorbitol, polysorbate 20, and histidine buffer in the appropriate concentration ranges. One of ordinary skill in the art will be familiar with conventional techniques used to prepare such compositions.

15 [0068] For example, immunogenic compositions can be prepared by mixing histidine buffer, sorbitol, and polysorbate 20 at the desired concentrations. Then, the HIV gp140 protein can be added. The pH of the composition can be adjusted before or after addition of the HIV gp140 protein. As another illustrative example, first a buffer solution containing histidine and sorbitol can be prepared. The HIV gp140 protein is prepared in buffer at the
20 desired concentration, and then added to the buffer solution containing histidine and sorbitol, followed by addition of Polysorbate at the target concentration. Adjuvant can be added last to obtain the final composition. The invention also provides methods for preparing a long-term, storage stable immunogenic composition that comprises HIV gp140 protein. In certain embodiments, such methods comprise: (i) providing an immunogenic composition according
25 to the invention (i.e. comprising 0.05-5 mg/mL HIV gp140 protein, 2-15% (w/v) sorbitol, 0.01-0.05% polysorbate 20, 5-20 mM histine buffer pH 5.5-7.0, water, and preferably 0.7-4.0 mg/mL aluminum phosphate), and (ii) storing said composition at 2-8°C for at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months. In certain embodiments, such methods comprise:

30 (i) admixing the following components to create an immunogenic composition comprising these components in amounts relative to the total volume of the composition:

- (a) 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
- (b) 2% to 15% (w/v) sorbitol;
- (c) 0.01 to 0.05% (w/v) polysorbate 20;

- (d) 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0,
- (e) water (preferably water for injection),
- (f) aluminum phosphate adjuvant, preferably at a concentration of 0.7-4 mg/mL;

5 and

(ii) storing the composition at 2-8°C for at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months.

Methods of Inducing an Immune Response

[0069] The invention also relates to methods of inducing an immune response against
10 human immunodeficiency virus (HIV) in a subject in need thereof with an immunogenic composition of the invention. The immune response can be against one or more HIV clades. The methods described herein also include administering an immunogenic composition of the invention in combination with one or more additional HIV antigens that are preferably expressed from one or more vectors, such as adenovirus vectors or MVA vectors, including
15 methods of priming and boosting an immune response.

[0070] In one general aspect, a method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject in need thereof comprises administering to the subject an effective amount of an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention. Any of the immunogenic
20 compositions described herein can be used in a method of inducing an immune response against HIV in a subject. Preferably, the composition comprises a stabilized trimeric HIV gp140 protein, such as an HIV clade C gp140 protein comprising the amino acid sequence of SEQ ID NO: 1, or an HIV mosaic gp140 protein comprising the amino acid sequence of SEQ ID NO: 2, or a mixture thereof. The composition can further comprise an adjuvant, such as
25 aluminum phosphate adjuvant. An exemplary embodiment of an immunogenic composition for use in the methods of the invention comprises, relative to the total volume of the composition,

- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;
- 30 b. 5% to 12% (w/v) sorbitol;
- c. 0.02% (w/v) polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5; and

- e. 0.7 to 4.0 mg/mL (e.g. 0.85 mg/mL or 3.84 mg/mL) aluminum phosphate adjuvant.

[0071] According to embodiments of the invention, “inducing an immune response” when used with reference to the methods and compositions described herein encompasses providing protective immunity and/or vaccinating a subject against an infection, such as an HIV infection, for prophylactic purposes, as well as causing a desired immune response or effect in a subject in need thereof against an infection, such as an HIV infection, for therapeutic purposes. Preferably, the methods of the invention are for prophylactic purposes, such as for providing protective immunity. The immune response can be a cellular immune response and/or a humoral immune response.

[0072] As used herein, the term “protective immunity” or “protective immune response” means that the vaccinated subject is able to control an infection with the pathogenic agent against which the vaccination was done. Usually, the subject having developed a “protective immune response” develops only mild to moderate clinical symptoms or no symptoms at all. Usually, a subject having a “protective immune response” or “protective immunity” against a certain agent will not die as a result of the infection with said agent.

[0073] Typically, administration of immunogenic compositions according to embodiments of the invention will have a prophylactic aim to generate an immune response against an HIV antigen before infection or development of symptoms. In other embodiments, the immunogenic compositions can be administered for post-exposure prophylactics. Immunogenic compositions of the invention can also be administered to a non-human mammal, such as for experimental purposes.

[0074] As used herein, “an effective amount” or “immunologically effective amount” means an amount of a composition sufficient to induce a desired immune effect or immune response in a subject in need thereof. In one embodiment, an effective amount means an amount sufficient to induce an immune response in a subject in need thereof. In certain embodiments, an effective amount means an amount sufficient to produce immunity in a subject in need thereof, e.g., provide a protective effect against a disease such as a viral infection. In certain embodiments, an effective amount means an amount sufficient to enhance an immune response in a subject in need thereof. For example, when used in combination with one or more other components or immunogenic compositions capable of effecting an immune response, such as in a prime-boost regimen, an effective amount can be

an amount sufficient to enhance the immune response induced by the one or more other components or immunogenic compositions.

[0075] An effective amount can vary depending upon a variety of factors, such as the physical condition of the subject, age, weight, health, etc.; the particular application, e.g., whether inducing immune response or providing protective immunity; and the particular disease, e.g., viral infection, for which immunity is desired. An effective amount can readily be determined by one of ordinary skill in the art in view of the present disclosure. As general guidance, when used with reference to an HIV gp140 protein an effective amount can range from, e.g. about 0.3 to about 3000 microgram (μg), e.g. 1-1000 μg , e.g. 10-500 μg , e.g. about 50, 100, 150, 200, 250, 300, 350, 400, 450 or 500 μg .

[0076] An effective amount of an immunogenic composition can be administered in a single composition, or in multiple compositions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 compositions (e.g., tablets, capsules and/or injectables), wherein the administration of the multiple compositions (e.g., tablets, capsules and/or injectables) collectively provides a subject with the immunogenically effective amount. It is also possible to administer an effective amount of an immunogenic composition to a subject, and subsequently administer another dose of an effective amount of an immunogenic composition to the same subject, in a so-called prime-boost regimen, as described in greater detail below.

[0077] According to embodiments of the invention, an immunogenic composition can be administered to a subject by any means known in the art including, but not limited to, oral (enteral) administration and parenteral injections. The parenteral injections could for instance include subcutaneous injection, intramuscular injection, or intradermal injection. Preferably, the immunogenic composition is administered by intramuscular injection.

[0078] It is also possible to administer immunogenic compositions of the invention together with one or more additional HIV antigens, or one or more vectors, such as adenovirus vectors, encoding one or more additional HIV antigens. As used herein, the terms "co-delivery," "co-administration," "administered together with," or "administered in combination with" refer to simultaneous administration of two or more components, such as an immunogenic composition comprising an HIV gp140 protein, or multiple viral expression vectors, such as adenovirus vectors. "Simultaneous administration" can be administration of the two or more components at least within the same day. When two components are "administered together with," they can be administered in separate compositions sequentially within a short time period, such as 24, 20, 16, 12, 8, or 4 hours, or within 1 hour or less, or they can be administered in a single composition at the same time. Non-limiting examples of

administration of immunogenic compositions of gp140 protein with one or more additional HIV antigens encoded by vectors such as adenoviral vectors, are provided in WO 2016/049287, the disclosure of which is herein incorporated by reference in its entirety.

[0079] Thus, in certain embodiments of the invention, a method of inducing an immune response further comprises administering to the subject an effective amount of a second immunogenic composition comprising one or more HIV antigens or one or more vectors encoding the HIV antigens. Any HIV antigen known to those skilled in the art in view of the present disclosure can be used, such as HIV Nef, Gag, Env, or Pol antigens or any antigenic portion or epitope or combination thereof. Mosaic HIV antigens can also be used.

Exemplary HIV antigens include, but are not limited to, mosaic Env, Gag, and/or Pol antigens and combinations thereof, such as those comprising the amino acid sequences of SEQ ID NOs: 3-12, or SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575). The additional HIV antigens can for instance be administered to the subject as isolated proteins or polypeptides or as vectors encoding these proteins or polypeptides.

[0080] Preferably, in the method comprising administering to the subject an effective amount of a second immunogenic composition, the second immunogenic composition comprises one or more vectors encoding one or more HIV antigens.

[0081] Any vector known to those skilled in the art in view of the present disclosure can be used. Preferably, the vector is an adenovirus vector, more preferably an adenovirus 26 vector. The preparation of recombinant adenoviral vectors is well known in the art.

Preparation of recombinant adenovirus 26 (rAd26) vectors is described, for example, in WO 2007/104792 and in Abbink *et al.*, (2007) *Virol* 81(9): 4654-63. Exemplary genome sequences of Ad26 are found in GenBank Accession EF 153474 and in SEQ ID NO:1 of WO 2007/104792. Examples of vectors useful for the invention for instance include those described in WO2012/082918, the disclosure of which is incorporated herein by reference in its entirety. Other adenovirus vectors that can be used in combination with immunogenic compositions of the invention include those described in WO 2016/049287 and PCT Application No. PCT/EP2016/081159, the disclosures of which are herein incorporated by reference in their entirety.

[0082] According to embodiments of the invention, adenovirus vectors can comprise one HIV antigen, or more than one HIV antigen, such as two, three, or four or more HIV antigens. Immunogenic compositions can comprise one or more adenovirus vectors, such as two, three, four or more HIV antigens, encoding one or more different HIV antigens. Also according to embodiments of the invention, a second composition can comprise one adenovirus vector, or more than one adenovirus vector, such as two, three, four or more adenovirus vectors. If a second composition comprises more than one adenovirus vector, the adenovirus vectors can encode the same or different HIV antigens.

[0083] Adenovirus vectors encoding one or more HIV antigens for use in the methods of the invention comprise nucleic acid encoding an HIV antigen that is operably linked to a promoter, meaning that the nucleic acid is under the control of a promoter. The promoter can be a homologous promoter (i.e., derived from the same genetic source as the vector) or a heterologous promoter (i.e., derived from a different vector or genetic source). Examples of suitable promoters include the cytomegalovirus (CMV) promoter and the Rous Sarcoma virus (RSV) promoter. Preferably, the promoter is located upstream of the nucleic acid within an expression cassette.

[0084] As general guidance, an "effective amount" when used with reference to adenovirus vectors, can range from about 10^8 viral particles to about 10^{12} viral particles, for example 10^8 , 10^9 , 10^{10} , 10^{11} , or 10^{12} viral particles. The preparation and use of immunogenic compositions comprising adenovirus vectors, such as adenovirus 26 vectors, are well known to those of ordinary skill in the art. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can also be included.

[0085] For instance recombinant adenovirus vector can be stored in the buffer that is also used for the Adenovirus World Standard (Hoganson *et al.*, 2002, *Bioprocessing J* 1: 43-8): 20 mM Tris pH 8, 25 mM NaCl, and 2.5% glycerol. Another useful adenovirus formulation buffer suitable for administration to humans is 20 mM Tris, 2 mM $MgCl_2$, 25 mM NaCl, 10% (w/v) sucrose, and 0.2% (w/v) polysorbate-80. Another formulation buffer that is suitable for recombinant adenovirus comprises 10-25 mM citrate buffer pH 5.9-6.2, 4-6% (w/w) hydroxypropyl-beta-cyclodextrin (HBCD), 70-100 mM NaCl, 0.018-0.035% (w/w) polysorbate-80, and optionally 0.3-0.45% (w/w) ethanol. Other buffers can be used, and several examples of suitable formulations for the storage and for pharmaceutical administration of purified vectors are known.

[0086] Administration of immunogenic compositions comprising the one or more additional HIV antigens or one or more adenovirus vectors encoding the one or more additional HIV antigens is typically intramuscular, intradermal or subcutaneous. However, other modes of administration such as intravenous, rectal, cutaneous, oral, nasal, etc. can be envisaged as well. Intramuscular administration of the immunogenic compositions can be achieved by using a needle to inject a suspension of the expression vectors, e.g. adenovirus vectors, and/or antigenic polypeptides. An alternative is the use of a needleless injection device to administer the composition (using, e.g., Biojector™) or a freeze-dried powder containing the vaccine.

5 [0087] In one embodiment, an immunogenic composition comprising a gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 3.

[0088] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 4.

15 [0089] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 5.

[0090] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 6.

25 [0091] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 7.

[0092] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 8.

[0093] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 9.

5 [0094] In one embodiment, an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 10.

[0095] In one embodiment, an immunogenic composition comprising an HIV gp140
10 protein according to an embodiment of the invention is used in combination with an adenovirus vector, preferably an adenovirus 26 vector, encoding a HIV antigen comprising the amino acid sequence of SEQ ID NO: 11, SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at
15 position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575), or SEQ ID NO: 12.

[0096] Upon administration of adenovirus vectors encoding one or more HIV antigens, the adenovirus vector expresses the encoded HIV antigens, such that the HIV antigens are
20 presented to the immune system of the subject, thereby inducing the required response to produce immunity, or induce an immune response. An immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention can be administered together with the one or more adenovirus vectors to prime the immune response, and/or subsequent to administration of the one or more adenovirus vectors to boost
25 the immune response.

[0097] Thus, in other embodiments of the invention, a method of inducing an immune response against an HIV in a subject in need thereof comprises (i) administering to the subject an effective amount of an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention, and preferably further comprising an
30 adjuvant, and (ii) administering to the subject an effective amount of a second immunogenic composition comprising one or more adenovirus vectors encoding one or more HIV antigens. Steps (i) and (ii) are conducted in either order, with one of the steps for priming immunization and the other for boosting immunization. Optionally, the method can further comprise administering one or more Modified Vaccinia Ankara (MVA) vectors encoding one

or more HIV antigens. MVA vectors can encode any HIV antigen described herein.

Preferably, the MVA vectors encode one or more HIV antigens selected from the group consisting of SEQ ID NOs: 3-12, or SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575).

[0098] Examples of adenovirus vectors, MVA vectors, and prime-boost regimens that can be used in combination with an immunogenic composition comprising an HIV gp140 protein according to an embodiment of the invention include those described in WO 2016/049287, the disclosure of which is herein incorporated by reference in its entirety.

[0099] For example, in one embodiment of the disclosed methods, one or more adenovirus vectors encoding one or more HIV antigens are used to prime the immune response. An immunogenic composition comprising an HIV gp140 protein according to the invention can be used together with the one or more adenovirus vectors for the priming immunization. The priming immunization can be administered only once, but can optionally also be administered multiple times, for example, initial priming administration at time 0, followed by another priming administration about 4-14 weeks, e.g. 10-14 weeks after the initial priming administration. The immunogenic composition comprising an HIV gp140 protein optionally together with one or more additional adenovirus or MVA vectors encoding one or more additional HIV antigens can be used to boost the immune response. A boosting immunization can also be administered once or multiple times, for example, first at about 22-26 weeks after the initial priming administration, followed by another boosting administration at about 46-50 weeks after the initial priming administration. The immune response induced by the immunization is monitored.

[00100] In other general aspects, the invention relates to vaccine combinations for inducing an immune response against a human immunodeficiency virus (HIV) in a subject in need thereof. According to embodiments of the invention, the vaccine combination comprises an immunogenic composition comprising an HIV gp140 protein, such as that comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; one or more adenovirus vectors, preferably adenovirus 26 vectors, encoding one or more HIV antigens, such as an HIV antigen comprising an amino acid sequence selected from the group consisting of SEQ ID NO:s 3 to 12, and SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to

Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575) and optionally one or more MVA vectors encoding one or more HIV antigens, such as an HIV antigen

5 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:s 3 to 12, and SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position

10 471) and T575C (Thr to Cys at position 575).

[00101] According to embodiments of the invention, the vaccine combinations can be used in any of the methods described herein for inducing an immune response against an HIV in a subject in need thereof, including for priming and boosting an immune response.

15 EMBODIMENTS

[00102] Embodiment 1 is an immunogenic composition comprising, relative to the total volume of the composition:

- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
- b. 2% to 15% (w/v) sorbitol;
- 20 c. 0.01 to 0.05% (w/v) polysorbate 20; and
- d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0.

[00103] Embodiment 2 is the immunogenic composition of embodiment 1, wherein the concentration of the HIV gp140 is 0.2 mg/mL.

[00104] Embodiment 3 is the immunogenic composition of embodiment 1, wherein the

25 concentration of the HIV gp140 is 1 mg/mL.

[00105] Embodiment 4 is the immunogenic composition of any of embodiments 1 to 3, wherein the concentration of sorbitol is 5% (w/v).

[00106] Embodiment 5 is the immunogenic composition of any of embodiments 1 to 3, wherein the concentration of sorbitol is 12% (w/v).

30 [00107] Embodiment 6 is the immunogenic composition of any of embodiments 1-5, wherein the concentration of polysorbate 20 is 0.02% (w/v).

[00108] Embodiment 7 is the immunogenic composition of any of embodiments 1-6, wherein the concentration of the histidine buffer is 10 mM, and the pH of the histidine buffer is 6.5.

5 [00109] Embodiment 8 is the immunogenic composition of any of embodiments 1-7, further comprising aluminum phosphate adjuvant, for instance at a concentration of 0.7-1.0 mg/mL, preferably at a concentration of 0.85 mg/mL.

[00110] Embodiment 9 is the immunogenic composition of any of embodiments 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 1.

10 [00111] Embodiment 10 is the immunogenic composition of any of embodiments 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 2.

[00112] Embodiment 11 is an immunogenic composition comprising, relative to the total volume of the composition,

- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;
- 15 b. 5% to 12% (w/v) sorbitol;
- c. 0.02% (w/v) polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5; and
- e. aluminum phosphate adjuvant, e.g. at a concentration of 0.7-4.0 mg/mL, e.g. 0.85 mg/mL or 3.84 mg/mL.

20 [00113] Embodiment 12 is the immunogenic composition of embodiment 11, comprising 0.2 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 and 5% (w/v) sorbitol.

[00114] Embodiment 13 is the immunogenic composition of embodiment 11, comprising 0.2 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 2 and 25 5% (w/v) sorbitol.

[00115] Embodiment 14 is the immunogenic composition of embodiment 11, comprising 0.2 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 and 12% (w/v) sorbitol.

30 [00116] Embodiment 15 is the immunogenic composition of embodiment 11, comprising 0.2 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 2 and 12% (w/v) sorbitol.

[00117] Embodiment 16 is the immunogenic composition of embodiment 11, comprising 1.0 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 and 5% (w/v) sorbitol.

5 [00118] Embodiment 17 is the immunogenic composition of embodiment 11, comprising 1.0 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 2 and 5% (w/v) sorbitol.

[00119] Embodiment 18 is the immunogenic composition of embodiment 11, comprising 1.0 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 and 12% (w/v) sorbitol.

10 [00120] Embodiment 19 is the immunogenic composition of embodiment 11, comprising 1.0 mg/mL HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 2 and 12% (w/v) sorbitol.

[00121] Embodiment 20 is an immunogenic composition according to any of embodiments 1 to 19 formulated for intramuscular injection.

15 [00122] Embodiment 21 is a method of preparing an immunogenic composition comprising admixing:

- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
- b. 2% to 15% (w/v) sorbitol;
- c. 0.01 to 0.05% polysorbate 20; and
- 20 d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0;

to thereby obtain the immunogenic composition.

[00123] Embodiment 22 is a method of inducing an immune response against an HIV in a subject in need thereof, comprising administering to the subject an effective amount of an
25 immunogenic composition comprising, relative to the total volume of the composition,

- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein;
- b. 2% to 15% (w/v) sorbitol;
- c. 0.01 to 0.05% polysorbate 20; and
- d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0.

30 [00124] Embodiment 23 is the method of embodiment 22, wherein the immunogenic composition comprises, relative to the total volume of the composition,

- a. 0.2 mg/mL to 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;

- b. 5% to 12% (w/v) sorbitol;
- c. 0.02% polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5; and
- e. aluminum phosphate adjuvant, e.g. at a concentration of 0.7-4.0 mg/mL, e.g. 0.85 mg/mL or 3.84 mg/mL.

5

[00125] Embodiment 24 is a method of inducing an immune response against an HIV in a subject in need thereof, comprising administering to the subject an effective amount of an immunogenic composition according to any one of embodiments 1 to 20, or to any one of embodiments 36-37.

- 10 [00126] Embodiment 25 is the method of any one of embodiments 22 to 24, further comprising administering to the subject an effective amount of one or more adenovirus vectors, preferably adenovirus 26 vectors, encoding one or more HIV antigens.

- [00127] Embodiment 26 is the method of any one of embodiments 22 to 25 further comprising administering to the subject an effective amount of one or more MVA vectors encoding one or more HIV antigens.

15

[00128] Embodiment 27 is the method of embodiment 25 or embodiment 26, wherein the one or more HIV antigens comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 3 to 12, and SEQ ID NO: 11 having one or more mutations selected from the group consisting of (i) I529P (Ile to Pro at position 529), (ii) K480E (Lys to Glu at position 480), and (iii) a combination of EK479-480RRRR (i.e. replacing GluLys at position 479 and 480 by four consecutive Arg residues), I529P (Ile to Pro at position 529), A471C (Ala to Cys at position 471) and T575C (Thr to Cys at position 575).

20

- [00129] Embodiment 28 is an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 36-37, which is stable at 2-8°C for at least six months.

25

[00130] Embodiment 29 is an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 36-37, which is stable at 2-8°C for at least 12 months, at least 18 months, at least 24 months, at least 30 months, at least 36 months.

- [00131] Embodiment 30 is an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 36-37, which is stable at 2-8°C for 6-72 months.

30

[00132] Embodiment 31 is an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 36-37, which is stable at 25°C for at least six months.

5 [00133] Embodiment 32 is an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 36-37, which is stable at 40°C for at least one week, preferably at least two weeks.

[00134] Embodiment 33 is a method for storing an immunogenic composition comprising HIV gp140 protein, the method comprising providing a immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 28-32, or to any one of
10 embodiments 36-37, and storing said composition at 2-8°C for at least one day, e.g. at least one week, e.g. at least one month, e.g. 1 day-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months.

[00135] Embodiment 34 is a method for preparing a long-term, storage stable immunogenic composition that comprises HIV gp140 protein, the method comprising: (i)
15 providing an immunogenic composition that comprises 0.05-5 mg/mL HIV gp140 protein, 2-15% (w/v) sorbitol, 0.01-0.05% polysorbate 20, 5-20 mM histine buffer pH 5.5-7.0, water, and preferably 0.7-4.0 mg/mL aluminum phosphate), and (ii) storing said composition at 2-8°C for at least one week, e.g. at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months.

20 [00136] Embodiment 35 is use of an immunogenic composition according to any one of embodiments 1-20, or to any one of embodiments 28-32, or to any one of embodiments 36-37, for administering to a subject, preferably a human subject, to induce an immune response against HIV, wherein the immunogenic composition prior to said administering has been stored at 2-8°C for at least one day, e.g. at least one week, e.g. at least two weeks, e.g. at least
25 three weeks, e.g. at least one month, e.g. at least two months, e.g. at least three months, e.g. at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 months.

[00137] Embodiment 36 is the immunogenic composition of any one of embodiments 1-9, wherein the HIV gp140 protein comprises a mixture of an HIV gp140 protein comprising the
30 amino acid sequence of SEQ ID NO:1 and an HIV gp140 protein comprising the amino acid sequence of SEQ NO: 2.

[00138] Embodiment 37 is the immunogenic composition of embodiment 36, wherein the HIV gp140 protein comprising the amino acid sequence of SEQ ID NO:1 and the HIV gp140

protein comprising the amino acid sequence of SEQ NO: 2 are present in the mixture at a 1:1 ratio.

EXAMPLES

5 [00139] **Example 1: Formulation Development Study for HIV Clade C gp140 Protein**

[00140] There are numerous possibilities for each component that can be included in a protein formulation, e.g., buffer, sugar, pH value, surfactant etc. For example, different possibilities for buffers can include phosphate, acetate, HEPES, Tris, MOPS, etc.; different possibilities for amino acids can include histidine, arginine, lysine, alanine, etc.; different possibilities for sugars can include sucrose, sorbitol, glycerol, mannitol, trehalose, etc.; and different possibilities for surfactant can include polysorbate 20, polysorbate 80, Tween-20, Tween-80, etc. There are also many other types of excipients, and numerous possibilities for each, that can further be included in a protein formulation, such as osmolytes (e.g., glycine, proline, glycerol, urea, etc.), salts (e.g., sodium chloride, potassium chloride, sodium sulfate, etc.), carbohydrates (e.g., lactose), proteins and polymers (e.g., HSA, gelatin, PVP, PLGA, PEG, etc.), chelators and antioxidants (e.g., EDTA, DTPA, ethanol, etc.), preservatives (e.g., benzyl alcohol, m-cresol, phenol, etc.), etc. See, e.g., Kamerzell et al. *Advanced Drug Delivery Reviews* (2011) 63, 1118-1159. Accordingly, there are many different theoretical combinations of components that could be used to identify a formulation. However, the most suitable formulation is dependent upon the particular protein in the formulation.

[00141] The inventors therefore set out to find improved formulations that could meet the complex requirements in the unpredictable art of protein formulation, in particular, an improved HIV gp140 formulation that enables drug product manufacturing meeting large late phase and commercial scale demands, and includes aluminum phosphate adjuvant and gp140 protein to be stored as drug product in single vials at refrigerated temperature, and prevents instability associated with certain components present in currently used formulations. The formulations were designed for storage in liquid form, but with the potential to be stored in lyophilized form and reconstituted in liquid prior to injection.

[00142] Formulation screening studies were designed to evaluate different buffers (histidine, phosphate, and acetate), buffer strengths (10 mM to 50 mM), sugars (sucrose and sorbitol from 2% to 12% w/v), surfactants (polysorbate 20 and polysorbate 80 from 0.02% to 1% w/v), and pH values from 4.5 to 7.5 on the stability of HIV clade C gp140 protein formulations. The parameters were varied as shown in Table 1.

[00143] **Table 1:** HIV clade C gp140 protein formulation study design

Buffer	Histidine (His)	Phosphate (Pho)	Acetate (Ace)
pH	5.5-6.5	6.5-7.5	4.5-5.5
Buffer Strength	10 mM, 20 mM, or 50 mM		
Sugar	Sucrose or sorbitol at 2% or 12% (w/v)		
Surfactant	Polysorbate 20 (PS20) or polysorbate 80 (PS80) at 0.02%, 0.05%, or 0.10% (w/v)		

[00144] The formulations were prepared by adding the buffer components at the pH value to be tested, followed by addition of sugar and surfactant. The pH was adjusted as necessary. Then, the clade C gp140 protein (SEQ ID NO: 1) was added to a concentration of 1 mg/mL or 0.2 mg/mL.

[00145] Formulation stability was analyzed using a SolvoVPE system to evaluate concentration and turbidity. Samples of each formulation were analyzed at time 0 (T_0), and then after stressing at 40°C for 24 hours (T_{24}). Formulation stability was also analyzed using dynamic light scattering (DLS).

[00146] SolvoVPE Analysis: A SolvoVPE (C Technologies, Inc.; Bridgeport, NJ, USA) was used to determine protein concentration by measuring the UV absorbance of samples of each formulation at 280 nm and 350 nm. The change in turbidity was determined from the difference in absorbance at 350 nm between T_0 and T_{24} measurements. For desired formulations, any change in turbidity should preferably be as small as possible. Increases in turbidity indicate that the protein is precipitating out of solution, and that the formulation is thus less stable. The results of the SolvoVPE analysis are shown in Fig. 1.

[00147] The results of the SolvoVPE analysis show that the acetate buffer formulations had the highest increase in turbidity (average change of +0.339), whereas phosphate buffer formulations showed a moderate increase (average change of +0.177), and histidine buffer formulations shows almost no change in turbidity (average change of -0.010). Since a large change in turbidity is undesirable, the turbidity data indicate that histidine buffer is the most optimal buffer of those tested for improving the stability of HIV gp140 protein.

[00148] Dynamic Light Scattering (DLS) Analysis: DLS was used to evaluate the colloidal stability, and specifically whether there was any protein aggregation in the protein formulations. The change in radius (R_h) from T_0 at 20°C to $T_{7 \text{ days}}$ at 70°C was measured. More specifically, the R_h was measured for the initial sample at 20°C. Then, the sample was heated to 70°C, and held at a temperature of 70°C for 7 days before measuring the final R_h . The difference in the initial R_h value and the final R_h values is plotted in Fig. 1B. A large

change in R_h indicates that there is protein aggregation, and that the formulation is thus less desirable.

[00149] The results of the DLS analysis show that formulations containing sorbitol had a lower change in R_h as compared to formulations containing sucrose. Since a larger change in R_h is undesirable, the DLS data indicate that sorbitol is the most optimal sugar of those tested for improving the stability of HIV gp140 protein.

[00150] The results of the above described studies also indicated that the sugar, sugar concentration, surfactant, surfactant concentration and protein concentration had an effect on the stability, so these parameters were further investigated as described in Example 2 below.

10

[00151] **Example 2: Effect of Sugar, Surfactant, and Protein Concentration on Stability of HIV Clade C gp140 Formulations**

[00152] HIV gp140 protein immunogenic formulations were prepared in a 10 mM histidine buffer, pH 6.0 ± 0.5 , with the following parameters being varied: sugar (sorbitol and sucrose), sugar concentration (2% and 12% w/v), polysorbate (PS20 and PS80), polysorbate concentration (0.02% and 0.1% w/v), and protein concentration (0.2 mg/mL and 1.0 mg/mL). The formulations were prepared by adding 10 mM histidine buffer, pH 6.0 ± 0.5 , followed by addition of sugar and surfactant. The pH was adjusted as necessary. HIV gp140 clade C protein (SEQ ID NO: 1) was added to the desired concentration. The formulations were then analyzed by High-Performance Size Exclusion Chromatography (HP-SEC), as described below.

20

[00153] The formulations prepared and tested are shown below in Table 2.

[00154] **Table 2:** HIV gp140 protein formulations

Formulation	Sugar	Sugar Concentration (% w/v)	Surfactant	Surfactant Concentration (% w/v)	Protein concentration (mg/mL)
1	sorbitol	12	PS20	0.02	0.2
2	sorbitol	12	PS80	0.1	0.2
3	sorbitol	2	PS20	0.1	0.2
4	sorbitol	2	PS20	0.1	0.2
5	sorbitol	2	PS80	0.02	1
6	sorbitol	12	PS80	0.02	1
7	sorbitol	12	PS20	0.02	1
8	sorbitol	2	PS80	0.1	1
9	sorbitol	12	PS80	0.1	1
10	sucrose	12	PS80	0.02	0.2
11	sucrose	2	PS20	0.02	0.2
12	sucrose	12	PS80	0.1	0.2
13	sucrose	2	PS80	0.02	0.2
14	sucrose	2	PS80	0.1	1
15	sucrose	2	PS20	0.02	1
16	sucrose	2	PS20	0.1	1
17	sucrose	12	PS20	0.1	1
18	sucrose	12	PS20	0.1	1

- 5 [00155] High-Performance Size Exclusion Chromatography (HP-SEC) Analysis: HP-SEC was used to analyze the amount of hexamer, trimer, and high/low molecular weight species in formulation samples by monitoring the absorbance at 280 nm. The HIV gp140 protein exists predominantly as a trimer. Some HIV gp140 protein hexamer species is also observed. Although the trimer species is the desired species, immunogenicity against HIV is observed
- 10 for both the trimer species and the hexamer species. High molecular weight (HMW) and low molecular weight (LMW) species in the formulations are undesired. In particular, the presence of LMW species indicates cleavage and/or degradation of the gp140 protein. HMW species may be caused by a number of factors, such as aggregation of the gp140 protein. Samples of each formulation were analyzed at time 0 (T_0), and then stressed at 40°C for 24
- 15 hours (T_{24}). Formulations containing 1 mg/mL clade C gp140 protein were diluted two-fold before injection into the HP-SEC system, and formulations containing 0.2 mg/mL clade C gp140 protein were not diluted prior to injection.

[00156] The results of the HP-SEC analysis are shown below in Table 3, and in Figs. 2A-2F. The results indicate that amount of trimer and hexamer for both T_0 and T_{24} samples

depends on the concentration of surfactant and HIV gp140 protein. Formulations having a lower surfactant concentration (0.02% w/v) had a higher observed value of trimer +hexamer species of the HIV gp140 protein, with less high/low molecular weight species observed (see Figs. 2B, 2D, and 2F), both before and after sample stressing. Formulations having a higher HIV gp140 protein concentration (1.0 mg/mL) also had a higher observed value of trimer +hexamer species of the HIV gp140 protein, with less high/low molecular weight species observed (see Figs. 2B and 2D), both before and after sample stressing (see Figs. 2A and 2C). Formulations containing polysorbate 20, as opposed to polysorbate 80, also had a lower amount of lower molecular weight species present (see Fig. 2E).

10

[00157] **Table 3:** Results of HP-SEC Analysis.

Formulation	High Molecular Weight Species (%)		Hexamer (%)		Trimer (%)		Low Molecular Weight Species (%)	
	T ₀	T ₂₄	T ₀	T ₂₄	T ₀	T ₂₄	T ₀	T ₂₄
1	0.57	0	10.69	10.13	88.05	89.87	0	0
2	0.22	0	8.48	9.55	80.08	85.39	11.22	5.06
3	0.2	0	9.15	9.51	84.47	85.77	0	4.72
4	0	0	9.26	9.56	84.63	86.71	0	3.73
5	0	0	10.72	12.27	88.41	87.73	0.86	0
6	0	0	10.78	11.6	88.44	88.4	0.78	0
7	0	0	11.08	11.7	88.6	88.3	0.32	0
8	0	0	10.46	11.67	87.33	88.33	2.21	0
9	0	0	10.6	11.57	86.91	88.43	2.48	0
10	0	0	9.79	10.02	88.17	89.98	2.05	0
11	0	0	10.52	10.54	88.75	89.46	0	0
12	0	0	8.9	9.23	79.79	83.51	11.31	7.26
13	0	0	9.74	10.58	87.58	89.42	2.68	0
14	0	0	10.37	11.82	87.38	87.98	2.25	0.2
15	0	0	10.91	12.15	88.77	87.85	0.32	0
16	0	0	10.57	11.42	87.71	87.72	1.72	0.86
17	0	0	10.63	11.45	88.51	88.43	0	0.12
18	0	0	10.74	11.54	88.28	88.46	0	0

[00158] The data shown in Table 3 indicates that the combination of sorbitol and histidine buffer is preferable to the combination of histidine buffer and sucrose. For examples, the formulations containing histidine buffer and sorbitol, such as formulations 1, 4, and 7, showed the least change between T₀ and T₂₄ in the amount of hexamer and trimer species as compared to that observed for the formulations containing histidine buffer and sucrose. This result was surprising because histidine buffer and sorbitol are not typically used in

combination for protein formulations, whereas histidine buffer and sucrose are often used in combination. It was thus unexpected that the most optimal formulation comprised histidine buffer (pH 6.0 ± 0.5) and sorbitol, rather than histidine buffer and sucrose. The above study also indicates that including polysorbate 20 as a surfactant (see, e.g., Fig. 2E) at a concentration of 0.2% (w/v) (see, e.g., Figs. 2B, 2D, and 2F) provides a formulation in which the stability of the HIV gp140 protein is further improved.

[00159] Advantages of the formulations identified herein over the one that is currently used for gp140 drug product in clinical trials, include that they use existing qualified compendial grade excipients that are readily available for large scale manufacturing and do not suffer from known issues that might negatively influence stability in the long term, and they enable storage of stable bulk drug substance and antigen drug product. Moreover, these formulations enable storage and stability of adjuvanted drug product as a single vial drug product at refrigerated temperature. These formulations are suitable for storage in liquid form, but also have the potential to be stored in lyophilized form and then reconstituted in liquid prior to injection, which is yet another advantage.

[00160] **Example 3: Stability Studies of HIV Mosaic gp140 Protein Formulations**

[00161] Two formulations containing HIV mosaic gp140 protein (SEQ ID NO: 2) were examined for stability in a freeze-thaw and temperature cycling study. The formulations tested are shown in Table 4.

[00162] **Table 4: HIV Mosaic gp140 Protein Formulations**

Formulation	Protein	Buffer	Sugar	Surfactant
F1	1.0 mg/mL	10 mM histidine, pH 6.5	12% sorbitol	0.02% PS20
F2	1.0 mg/mL	10 mM histidine, pH 6.5	2% sorbitol	0.02% PS20

[00163] The formulations were subjected to multiple freeze-thaw cycles. One freeze-thaw cycle was conducted by freezing at -80°C or -40°C for 24 hours, followed by thawing at -2°C to 8°C for 24 hours. Samples were analyzed at the end of 1, 3, and 5 cycles of freeze-thaw by measuring the absorbance at 280 nm (concentration) and 350 nm (turbidity). The results are shown in Fig. 3A and Fig. 3B.

[00164] The results show that the absorbance at 350 nm and 280 nm was largely unchanged for both formulations F1 and F2 after multiple freeze-thaw cycles, indicating that

the concentration and turbidity of the formulation were relatively unaffected. This demonstrates that the HIV gp140 protein in the formulations is stable to freeze-thaw.

[00165] **Example 4: Long Term Stability Study of HIV gp140 protein formulations**

5 [00166] The stability of HIV gp140 protein compositions in histidine buffer, both with and without adjuvant according to embodiments of the invention was compared to the stability of an HIV gp140 protein composition formulated in HEPES buffer, both with and without adjuvant. The compositions tested are shown in Table 5. All formulations contained 0.2 mg/mL HIV clade C gp140 protein (SEQ ID NO: 1).

10

[00167] **Table 5: HIV gp140 protein formulations for long term stability study.**

Formulation	Buffer Composition	Adjuvant?
1	20 mM HEPES, pH 6.5 90 mM NaCl 4% (w/v) sucrose 0.02% polysorbate 80	No adjuvant
2	10 mM histidine buffer, pH 6.5 12% (w/v) sorbitol 0.02% (w/v) polysorbate 20	No adjuvant
3	10 mM histidine buffer, pH 6.5 2% (w/v) sorbitol 0.02% (w/v) polysorbate 20	No adjuvant
4	10 mM histidine buffer, pH 6.5 5% (w/v) sorbitol 0.02% (w/v) polysorbate 20	No adjuvant
5	20 mM HEPES, pH 6.5 90 mM NaCl 4% (w/v) sucrose 0.02% polysorbate 80	+ aluminum phosphate adjuvant (0.85 mg/mL)
6	10 mM histidine buffer, pH 6.5 12% (w/v) sorbitol 0.02% (w/v) polysorbate 20	+ aluminum phosphate adjuvant (0.85 mg/mL)
7	10 mM histidine buffer, pH 6.5 2% (w/v) sorbitol 0.02% (w/v) polysorbate 20	+ aluminum phosphate adjuvant (0.85 mg/mL)
8	10 mM histidine buffer, pH 6.5 5% (w/v) sorbitol 0.02% (w/v) polysorbate 20	+ aluminum phosphate adjuvant (0.85 mg/mL)

[00168] Compositions were stored at 2°C to 8°C; 25°C and 60% relative humidity (RH); and 40°C and 75% RH. The study is ongoing, and samples are tested after storage for 2 weeks, 1, 2, 3, 6, 9, 12, 18, 24, 30, and 36 months.

15

[00169] Samples were tested by reduced SDS after storage for up to three months. Under reducing conditions, as the SDS-PAGE was performed, the trimeric and hexameric forms were reduced to a monomeric form that showed up a single band on the gel. Any degradation of the protein to lower molecular weight species resulted in a change (decrease) in the monomeric form of the protein observed on the gel. The data for samples stored at 25°C and 60% RH, and at 40°C and 75% RH are shown in Figs. 4A-4D. The data show that all formulations were stable under storage at 25°C and 60% RH both with and without aluminum phosphate adjuvant for up to three months (Figs. 4A and 4C). However, formulations containing histidine buffer and sorbitol were more stable than the formulation containing HEPES and sucrose (Figs. 4B and 4D) when stored at 40°C and 75% RH, both with and without aluminum phosphate adjuvant. In addition, after six months storage at 25°C the histidine formulated material with 12% sorbitol, without aluminum phosphate adjuvant, showed better stability compared to the HEPES buffered formulation as measured by SDS-PAGE (smaller change in % compared to initial measurement; data not shown). Moreover, gp140 that was formulated with histidine buffer, sorbitol and aluminum phosphate was observed to be stable at 25°C for at least six months (data not shown). Also when formulated with histidine buffer and sorbitol, at higher concentrations of aluminum phosphate adjuvant (3.84 mg/mL), the HIV gp140 protein was observed to be stable at 25°C for at least six months and at 40°C for at least three months as measured by reduced SDS PAGE (less than 25% reduction, data not shown; while measurements using ELISA showed stability (less than 50% reduction) at 40°C for at least two weeks, data not shown). These data further indicate that HIV gp140 protein formulations containing histidine buffer and sorbitol have enhanced stability, and can thus be stored as an adjuvanted drug product in a single vial at elevated temperatures, which is an advantage as it is often difficult to formulate adjuvanted protein that is stable to storage at elevated temperatures. This means that the drug product with adjuvant can be stored in a single vial at a manufacturing or a fill-and-finish site, and does not require separate storage with mixing in a pharmacy or at bed-side just prior to administration. Apart from being economically beneficial, this is a huge advantage especially for an HIV vaccine product that is intended to be also used in many places where capacity and facilities may be limited. It is also an advantage of limiting the number of operations to be performed with the drug product on site where a large number of subjects are to be vaccinated in a single campaign. Thus, the formulations of the invention surprisingly improve the practical properties for use of the final vaccine, especially in resource-limited settings.

[00170] A combination of two HIV gp140 proteins, one having SEQ ID NO: 1 and one having SEQ ID NO: 2 is mixed (total protein concentration 0.2-1.0 mg/mL, e.g. 0.1 mg/mL for each protein resulting in a total concentration of gp140 protein of 0.2 mg/mL) and tested in the preferred formulation, i.e. 2% to 15% (w/v) sorbitol; 0.01 to 0.05% (w/v), e.g. 0.02%, polysorbate 20; and 5 to 20 mM, e.g. 10 mM, histidine buffer at a pH of 5.5 to 7.0, e.g. pH 6.5, and preferably aluminum phosphate, e.g. 0.7-4 mg/mL, e.g. 0.85 or 3.84 mg/mL, using methods as described above. This composition is also expected to be stable for at least six months at 2-8°C, like the individual proteins in this formulation as indicated above.

[00171] It is understood that the examples and embodiments described herein are for illustrative purposes only, and that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the invention as defined by the appended claims.

REFERENCES

LITERATURE

1. Abbink *et al.*, (2007) *Virology* 81(9): 4654-63.
- 5 2. Baicu *et al.* *Cryobiology* (2002) 45(1) 33-48;
3. Barouch *et al.*, *Nat Med* 2010, 16: 319-323
4. Barouch DH *et al.* (2015) *Science* 349: 320-324.
5. Barouch *et al.*, *Cell* 155:1-9, 2013
6. Harris A *et al.* (2011). *Proc Natl Acad Sci USA* 108: 11440-11445.
- 10 7. Hoganson *et al.*, 2002, *Bioprocessing J* 1: 43-8
8. Kamerzell *et al.* *Advanced Drug Delivery Reviews* (2011) 63, 1118-1159
9. Kovacs JM *et al.* (2012) *Proc Natl Acad Sci USA* 109: 12111-12116
10. Kerzell *et al.* *Advanced Drug Delivery Reviews* (2011) 63, 1118-1159
11. Lepe-Zuniga *et al.* *J. Immunol. Methods* (1987) 103(1), 145;
- 15 12. Nkolola *et al.* *J. Virol.* (2014) 88(17), 9538-9552.
13. Nkolola *et al.* *J. Virol.* (2010) 84(7), 3270-3279.
14. Sanders RW *et al.*, (2002) *J. Virol.* 76: 8875-8889.
15. Sanders RW *et al.* (2015) *Science* 349(6244): aac4223, doi: [10.1126/science.aac4223](https://doi.org/10.1126/science.aac4223)
16. Uchiyama, *Biochimica Biophysica Acta* (2014) 1844, 2041-2052
- 20 17. Zhang C W-H *et al.* (2001) *J Biol Chem* 276: 39577-39585.
18. Zigler *et al.* *In Vitro Cell. Dev. Biol.* (1985) 21(5), 282-287

PATENT DOCUMENTS:

1. WO 2010/042942
- 25 2. WO 2014/107744
3. US20120076812;
4. WO 2016/049287
5. WO 2010/059732
6. US20120076812
- 30 7. WO 2007/104792
8. PCT/EP2016/081159

CLAIMS

1. An immunogenic composition comprising, relative to the total volume of the composition:
 - 5 a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein or of a mixture of at least two HIV gp140 proteins;
 - b. 2% to 15% (w/v) sorbitol;
 - c. 0.01 to 0.05% (w/v) polysorbate 20; and
 - d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0.
- 10 2. The immunogenic composition of claim 1, wherein the concentration of the HIV gp140 protein or of the mixture of HIV gp140 proteins is 0.2 mg/mL.
3. The immunogenic composition of claim 1, wherein the concentration of the HIV gp140 protein or of the mixture of HIV gp140 proteins is 1 mg/mL.
4. The immunogenic composition of any of claims 1 to 3, wherein the concentration of sorbitol is 5% (w/v).
- 15 5. The immunogenic composition of any of claims 1 to 3, wherein the concentration of sorbitol is 12% (w/v).
6. The immunogenic composition of any of claims 1-5, wherein the concentration of polysorbate 20 is 0.02% (w/v).
- 20 7. The immunogenic composition of any of claims 1-6, wherein the concentration of the histidine buffer is 10 mM, and the pH of the histidine buffer is 6.5.
8. The immunogenic composition of any of claims 1-7, further comprising aluminum phosphate adjuvant, e.g. at 0.7-4.0 mg/mL, e.g. at 0.85 mg/mL or 3.84 mg/mL.
9. The immunogenic composition of any of claims 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 1.
- 25 10. The immunogenic composition of any of claims 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 2.
11. The immunogenic composition of any of claims 1-8, comprising a mixture of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO:1 and an HIV gp140 protein comprising the amino acid sequence of SEQ NO: 2.
- 30 12. An immunogenic composition comprising, relative to the total volume of the composition,
 - a. 0.2 mg/mL or 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or of a mixture of an HIV gp140

protein comprising the amino acid sequence of SEQ ID NO:1 and an HIV gp140 protein comprising the amino acid sequence of SEQ NO: 2;

- b. 5% or 12% (w/v) sorbitol;
- c. 0.02% (w/v) polysorbate 20;
- d. 10 mM histidine buffer at a pH of 6.5; and
- e. aluminum phosphate adjuvant, e.g. 0.85 mg/mL or 3.84 mg/mL.

13. A method of preparing an immunogenic composition comprising admixing:

- a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein or of at least two HIV gp140 proteins;
- b. 2% to 15% (w/v) sorbitol;
- c. 0.01 to 0.05% polysorbate 20; and
- d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0;

to thereby obtain the immunogenic composition.

14. A method according to claim 13, further comprising admixing:

e.g. 0.7-4.0 mg/mL aluminum phosphate adjuvant.

15. The immunogenic composition of any one of claims 1-12, which is stable upon storage at 2-8°C for at least six months.

16. A method for preparing a long-term, storage stable immunogenic composition that comprises HIV gp140 protein, the method comprising: (i) providing an immunogenic composition according to any one of claims 1-12 or 15, and (ii) storing said composition at 2-8°C for at least one week, e.g. at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months.

17. Use of an immunogenic composition according to any one of claims 1-12 or 15 for administering to a subject, preferably a human subject, to induce an immune response against HIV, wherein the immunogenic composition prior to said administering has been stored at 2-8°C for between one day and 36 months.

FIG 1A




FIG 1B




FIG. 2B




FIG. 2A




FIG 2D





FIG 2C



4/7

FIG 2E





FIG 2F



5/7

FIG 3A





FIG 3B



6/7

FIG 4A





FIG 4B



717

FIG 4C





FIG 4D



SEQUENCE LISTING

<110> Janssen Vaccines & Prevention B.V.

<120> HIV Vaccine Formulation

<130> 0266 WO 00 ORD

<160> 14

<170> PatentIn version 3.5

<210> 1

<211> 679

<212> PRT

<213> Artificial Sequence

<220>

<223> HIV clade C gp140 protein

<400> 1

Ala Glu Asn Leu Trp Val Gly Asn Met Trp Val Thr Val Tyr Tyr Gly
1 5 10 15

Val Pro Val Trp Thr Asp Ala Lys Thr Thr Leu Phe Cys Ala Ser Asp
 20 25 30

Thr Lys Ala Tyr Asp Arg Glu Val His Asn Val Trp Ala Thr His Ala
 35 40 45

Cys Val Pro Thr Asp Pro Asn Pro Gln Glu Ile Val Leu Glu Asn Val
 50 55 60

Thr Glu Asn Phe Asn Met Trp Lys Asn Asp Met Val Asp Gln Met His
65 70 75 80

Glu Asp Ile Ile Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys
 85 90 95

Leu Thr Pro Leu Cys Val Thr Leu His Cys Thr Asn Ala Thr Phe Lys
 100 105 110

Asn Asn Val Thr Asn Asp Met Asn Lys Glu Ile Arg Asn Cys Ser Phe
115 120 125

Asn Thr Thr Thr Glu Ile Arg Asp Lys Lys Gln Gln Gly Tyr Ala Leu
130 135 140

Phe Tyr Arg Pro Asp Ile Val Leu Leu Lys Glu Asn Arg Asn Asn Ser
145 150 155 160

Asn Asn Ser Glu Tyr Ile Leu Ile Asn Cys Asn Ala Ser Thr Ile Thr
165 170 175

Gln Ala Cys Pro Lys Val Asn Phe Asp Pro Ile Pro Ile His Tyr Cys
180 185 190

Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys Asn Asn Lys Thr Phe Ser
195 200 205

Gly Lys Gly Pro Cys Asn Asn Val Ser Thr Val Gln Cys Thr His Gly
210 215 220

Ile Lys Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala
225 230 235 240

Glu Lys Glu Ile Ile Ile Arg Ser Glu Asn Leu Thr Asp Asn Val Lys
245 250 255

Thr Ile Ile Val His Leu Asn Lys Ser Val Glu Ile Val Cys Thr Arg
260 265 270

Pro Asn Asn Asn Thr Arg Lys Ser Met Arg Ile Gly Pro Gly Gln Thr
275 280 285

Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg Gln Ala Tyr Cys
290 295 300

Asn Ile Ser Gly Ser Lys Trp Asn Glu Thr Leu Lys Arg Val Lys Glu
305 310 315 320

Lys Leu Gln Glu Asn Tyr Asn Asn Asn Lys Thr Ile Lys Phe Ala Pro
 325 330 335

Ser Ser Gly Gly Asp Leu Glu Ile Thr Thr His Ser Phe Asn Cys Arg
 340 345 350

Gly Glu Phe Phe Tyr Cys Asn Thr Thr Arg Leu Phe Asn Asn Asn Ala
 355 360 365

Thr Glu Asp Glu Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile
 370 375 380

Asn Met Trp Gln Gly Val Gly Arg Ala Met Tyr Ala Pro Pro Ile Ala
 385 390 395 400

Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr Gly Leu Leu Leu Val Arg
 405 410 415

Asp Gly Gly Glu Asp Asn Lys Thr Glu Glu Ile Phe Arg Pro Gly Gly
 420 425 430

Gly Asn Met Lys Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val
 435 440 445

Ile Glu Leu Lys Pro Leu Gly Ile Ala Pro Thr Gly Ala Lys Glu Arg
 450 455 460

Val Val Glu Arg Glu Glu Arg Ala Val Gly Ile Gly Ala Val Phe Leu
 465 470 475 480

Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Leu Thr
 485 490 495

Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Ser Ile Val Gln Gln Gln
 500 505 510

Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu
 515 520 525

Thr Val Trp Gly Ile Lys Gln Leu Gln Thr Arg Val Leu Ala Ile Glu
 530 535 540

Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly
 545 550 555 560

Lys Leu Ile Cys Thr Thr Asn Val Pro Trp Asn Ser Ser Trp Ser Asn
 565 570 575

Lys Ser Gln Thr Asp Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp
 580 585 590

Arg Glu Ile Ser Asn Tyr Thr Asp Thr Ile Tyr Arg Leu Leu Glu Asp
 595 600 605

Ser Gln Thr Gln Gln Glu Lys Asn Glu Lys Asp Leu Leu Ala Leu Asp
 610 615 620

Ser Trp Lys Asn Leu Trp Ser Trp Phe Asp Ile Ser Asn Trp Leu Trp
 625 630 635 640

Tyr Ile Lys Ser Arg Ile Glu Gly Arg Gly Ser Gly Gly Tyr Ile Pro
 645 650 655

Glu Ala Pro Arg Asp Gly Gln Ala Tyr Val Arg Lys Asp Gly Glu Trp
 660 665 670

Val Leu Leu Ser Thr Phe Leu
 675

<210> 2

<211> 695

<212> PRT

<213> Artificial Sequence

<220>

<223> HIV mosaic gp140 protein

<400> 2

Ala Gly Lys Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys
1 5 10 15

Glu Ala Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp
 20 25 30

Thr Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp
 35 40 45

Pro Asn Pro Gln Glu Val Val Leu Glu Asn Val Thr Glu Asn Phe Asn
 50 55 60

Met Trp Lys Asn Asn Met Val Glu Gln Met His Glu Asp Ile Ile Ser
65 70 75 80

Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys
 85 90 95

Val Thr Leu Asn Cys Thr Asp Asp Val Arg Asn Val Thr Asn Asn Ala
 100 105 110

Thr Asn Thr Asn Ser Ser Trp Gly Glu Pro Met Glu Lys Gly Glu Ile
 115 120 125

Lys Asn Cys Ser Phe Asn Ile Thr Thr Ser Ile Arg Asn Lys Val Gln
 130 135 140

Lys Gln Tyr Ala Leu Phe Tyr Lys Leu Asp Val Val Pro Ile Asp Asn
145 150 155 160

Asp Ser Asn Asn Thr Asn Tyr Arg Leu Ile Ser Cys Asn Thr Ser Val
 165 170 175

Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His
 180 185 190

Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Lys
 195 200 205

Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln Cys Thr
 210 215 220

His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser
 225 230 235 240

Leu Ala Glu Glu Glu Val Val Ile Arg Ser Glu Asn Phe Thr Asn Asn
 245 250 255

Ala Lys Thr Ile Met Val Gln Leu Asn Val Ser Val Glu Ile Asn Cys
 260 265 270

Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile His Ile Gly Pro Gly
 275 280 285

Arg Ala Phe Tyr Thr Ala Gly Asp Ile Ile Gly Asp Ile Arg Gln Ala
 290 295 300

His Cys Asn Ile Ser Arg Ala Asn Trp Asn Asn Thr Leu Arg Gln Ile
 305 310 315 320

Val Glu Lys Leu Gly Lys Gln Phe Gly Asn Asn Lys Thr Ile Val Phe
 325 330 335

Asn His Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn
 340 345 350

Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Lys Leu Phe Asn Ser
 355 360 365

Thr Trp Thr Trp Asn Asn Ser Thr Trp Asn Asn Thr Lys Arg Ser Asn
 370 375 380

Asp Thr Glu Glu His Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile
 385 390 395 400

Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Arg
 405 410 415

Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg
 420 425 430

Asp Gly Gly Asn Asp Thr Ser Gly Thr Glu Ile Phe Arg Pro Gly Gly
 435 440 445

Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val
 450 455 460

Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Glu Arg
 465 470 475 480

Val Val Gln Arg Glu Glu Arg Ala Val Gly Ile Gly Ala Val Phe Leu
 485 490 495

Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Met Thr
 500 505 510

Leu Thr Val Gln Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln
 515 520 525

Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu
 530 535 540

Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Val Leu Ala Val Glu
 545 550 555 560

Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly
 565 570 575

Lys Leu Ile Cys Thr Thr Thr Val Pro Trp Asn Ala Ser Trp Ser Asn
 580 585 590

Lys Ser Leu Asp Lys Ile Trp Asn Asn Met Thr Trp Met Glu Trp Glu
 595 600 605

Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile Tyr Thr Leu Ile Glu Glu
 610 615 620

Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp
 625 630 635 640

Lys Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Ser Asn Trp Leu Trp
 645 650 655

Tyr Ile Lys Ser Arg Ile Glu Gly Arg Gly Ser Gly Gly Tyr Ile Pro
 660 665 670

Glu Ala Pro Arg Asp Gly Gln Ala Tyr Val Arg Lys Asp Gly Glu Trp
 675 680 685

Val Leu Leu Ser Thr Phe Leu
 690 695

<210> 3

<211> 660

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos1Env mosaic HIV antigen

<400> 3

Met Arg Val Thr Gly Ile Arg Lys Asn Tyr Gln His Leu Trp Arg Trp
 1 5 10 15

Gly Thr Met Leu Leu Gly Ile Leu Met Ile Cys Ser Ala Ala Gly Lys
 20 25 30

Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Thr
 35 40 45

Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val
 50 55 60

His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro
 65 70 75 80

Gln Glu Val Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met Trp Lys
 85 90 95

Asn Asn Met Val Glu Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp
 100 105 110

Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu
 115 120 125

Asn Cys Thr Asp Asp Val Arg Asn Val Thr Asn Asn Ala Thr Asn Thr
 130 135 140

Asn Ser Ser Trp Gly Glu Pro Met Glu Lys Gly Glu Ile Lys Asn Cys
 145 150 155 160

Ser Phe Asn Ile Thr Thr Ser Ile Arg Asn Lys Val Gln Lys Gln Tyr
 165 170 175

Ala Leu Phe Tyr Lys Leu Asp Val Val Pro Ile Asp Asn Asp Ser Asn
 180 185 190

Asn Thr Asn Tyr Arg Leu Ile Ser Cys Asn Thr Ser Val Ile Thr Gln
 195 200 205

Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala
 210 215 220

Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys Lys Phe Asn Gly
 225 230 235 240

Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln Cys Thr His Gly Ile
 245 250 255

Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu
 260 265 270

Glu Glu Val Val Ile Arg Ser Glu Asn Phe Thr Asn Asn Ala Lys Thr
 275 280 285

Ile Met Val Gln Leu Asn Val Ser Val Glu Ile Asn Cys Thr Arg Pro
 290 295 300

Asn Asn Asn Thr Arg Lys Ser Ile His Ile Gly Pro Gly Arg Ala Phe
 305 310 315 320

Tyr Thr Ala Gly Asp Ile Ile Gly Asp Ile Arg Gln Ala His Cys Asn
 325 330 335

Ile Ser Arg Ala Asn Trp Asn Asn Thr Leu Arg Gln Ile Val Glu Lys
 340 345 350

Leu Gly Lys Gln Phe Gly Asn Asn Lys Thr Ile Val Phe Asn His Ser
 355 360 365

Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys Gly Gly
 370 375 380

Glu Phe Phe Tyr Cys Asn Ser Thr Lys Leu Phe Asn Ser Thr Trp Thr
 385 390 395 400

Trp Asn Asn Ser Thr Trp Asn Asn Thr Lys Arg Ser Asn Asp Thr Glu
 405 410 415

Glu His Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Met Trp
 420 425 430

Gln Glu Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Arg Gly Gln Ile
 435 440 445

Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly
 450 455 460

Asn Asp Thr Ser Gly Thr Glu Ile Phe Arg Pro Gly Gly Gly Asp Met
 465 470 475 480

Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Lys Ile
 485 490 495

Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln
 500 505 510

Ser Glu Lys Ser Ala Val Gly Ile Gly Ala Val Phe Leu Gly Phe Leu
 515 520 525

Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val
 530 535 540

Gln Ala Arg Leu Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu
 545 550 555 560

Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp
 565 570 575

Gly Ile Lys Gln Leu Gln Ala Arg Val Leu Ala Val Glu Arg Tyr Leu
 580 585 590

Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile
 595 600 605

Cys Thr Thr Thr Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu
 610 615 620

Asp Lys Ile Trp Asn Asn Met Thr Trp Met Glu Trp Glu Arg Glu Ile
 625 630 635 640

Asn Asn Tyr Thr Ser Leu Ile Tyr Thr Leu Ile Glu Glu Ser Gln Asn
 645 650 655

Gln Gln Glu Lys
 660

<210> 4

<211> 684

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos2Env mosaic HIV antigen

<400> 4

Met Arg Val Arg Gly Ile Gln Arg Asn Trp Pro Gln Trp Trp Ile Trp
 1 5 10 15

Gly Ile Leu Gly Phe Trp Met Ile Ile Ile Cys Arg Val Met Gly Asn
 20 25 30

Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Glu Ala Lys
 35 40 45

Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Glu Lys Glu Val
 50 55 60

His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro
 65 70 75 80

Gln Glu Met Val Leu Glu Asn Val Thr Glu Asn Phe Asn Met Trp Lys
 85 90 95

Asn Asp Met Val Asp Gln Met His Glu Asp Ile Ile Arg Leu Trp Asp
 100 105 110

Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu
 115 120 125

Glu Cys Arg Asn Val Arg Asn Val Ser Ser Asn Gly Thr Tyr Asn Ile
 130 135 140

Ile His Asn Glu Thr Tyr Lys Glu Met Lys Asn Cys Ser Phe Asn Ala
 145 150 155 160

Thr Thr Val Val Glu Asp Arg Lys Gln Lys Val His Ala Leu Phe Tyr
 165 170 175

Arg Leu Asp Ile Val Pro Leu Asp Glu Asn Asn Ser Ser Glu Lys Ser
 180 185 190

Ser Glu Asn Ser Ser Glu Tyr Tyr Arg Leu Ile Asn Cys Asn Thr Ser
 195 200 205

Ala Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Asp Pro Ile Pro Ile
 210 215 220

His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys Asn Asn Lys
 225 230 235 240

Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser Thr Val Gln Cys
 245 250 255

Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly
 260 265 270

Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu Asn Leu Thr Asn
 275 280 285

Asn Ala Lys Thr Ile Ile Val His Leu Asn Glu Thr Val Asn Ile Thr
 290 295 300

Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gly Pro
 305 310 315 320

Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg Gln
 325 330 335

Ala His Cys Asn Leu Ser Arg Asp Gly Trp Asn Lys Thr Leu Gln Gly
 340 345 350

Val Lys Lys Lys Leu Ala Glu His Phe Pro Asn Lys Thr Ile Asn Phe
 355 360 365

Thr Ser Ser Ser Gly Gly Asp Leu Glu Ile Thr Thr His Ser Phe Asn
 370 375 380

Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Gly Leu Phe Asn Gly
 385 390 395 400

Thr Tyr Met Pro Asn Gly Thr Asn Ser Asn Ser Ser Ser Asn Ile Thr
 405 410 415

Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly
 420 425 430

Arg Ala Met Tyr Ala Pro Pro Ile Ala Gly Asn Ile Thr Cys Arg Ser
 435 440 445

Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Ser Asn Asn Gly
 450 455 460

Val Pro Asn Asp Thr Glu Thr Phe Arg Pro Gly Gly Gly Asp Met Arg
 465 470 475 480

Asn Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Glu Val Lys
 485 490 495

Pro Leu Gly Val Ala Pro Thr Glu Ala Lys Arg Arg Val Val Glu Ser
 500 505 510

Glu Lys Ser Ala Val Gly Ile Gly Ala Val Phe Leu Gly Ile Leu Gly
 515 520 525

Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln
 530 535 540

Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Ser Asn Leu Leu
 545 550 555 560

Arg Ala Ile Glu Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly
 565 570 575

Ile Lys Gln Leu Gln Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu Gln
 580 585 590

Asp Gln Gln Leu Leu Gly Leu Trp Gly Cys Ser Gly Lys Leu Ile Cys
 595 600 605

Thr Thr Ala Val Pro Trp Asn Thr Ser Trp Ser Asn Lys Ser Gln Thr
 610 615 620

Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp Lys Glu Ile Gly
 625 630 635 640

Asn Tyr Thr Gly Glu Ile Tyr Arg Leu Leu Glu Glu Ser Gln Asn Gln
 645 650 655

Gln Glu Lys Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys Asn
 660 665 670

Leu Trp Asn Trp Phe Asp Ile Thr Asn Trp Leu Trp
 675 680

<210> 5

<211> 840

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos1Pol mosaic HIV antigen

<400> 5

Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
 1 5 10 15

Gly Met Asp Gly Pro Arg Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
 20 25 30

Ile Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu Lys Glu Gly Lys
 35 40 45

Ile Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Val Phe Ala
 50 55 60

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
 65 70 75 80

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
 85 90 95

Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala
 100 105 110

Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Gly Phe Arg Lys
 115 120 125

Tyr Thr Ala Phe Thr Ile Pro Ser Thr Asn Asn Glu Thr Pro Gly Ile
 130 135 140

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
 145 150 155 160

Ile Phe Gln Cys Ser Met Thr Arg Ile Leu Glu Pro Phe Arg Ala Lys
 165 170 175

Asn Pro Glu Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
 180 185 190

Ser Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile Glu Glu Leu Arg
 195 200 205

Glu His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln
 210 215 220

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
 225 230 235 240

Trp Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp Ser Trp Thr Val
 245 250 255

Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
 260 265 270

Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Ala
 275 280 285

Lys Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu Ala Glu Leu Glu
 290 295 300

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 305 310 315 320

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly His
 325 330 335

Asp Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
 340 345 350

Thr Gly Lys Tyr Ala Lys Met Arg Thr Ala His Thr Asn Asp Val Lys
 355 360 365

Gln Leu Thr Glu Ala Val Gln Lys Ile Ala Met Glu Ser Ile Val Ile
 370 375 380

Trp Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln Lys Glu Thr Trp
 385 390 395 400

Glu Thr Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
 405 410 415

Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
 420 425 430

Lys Asp Pro Ile Ala Gly Val Glu Thr Phe Tyr Val Ala Gly Ala Ala
 435 440 445

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asp Arg Gly
 450 455 460

Arg Gln Lys Ile Val Ser Leu Thr Glu Thr Thr Asn Gln Lys Thr Ala
 465 470 475 480

Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly Ser Glu Val Asn
 485 490 495

Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
 500 505 510

Asp Lys Ser Glu Ser Glu Leu Val Asn Gln Ile Ile Glu Gln Leu Ile
 515 520 525

Lys Lys Glu Arg Val Tyr Leu Ser Trp Val Pro Ala His Lys Gly Ile
 530 535 540

Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Ser Gly Ile Arg Lys
 545 550 555 560

Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Glu Glu His Glu Lys
 565 570 575

Tyr His Ser Asn Trp Arg Ala Met Ala Ser Asp Phe Asn Leu Pro Pro
 580 585 590

Val Val Ala Lys Glu Ile Val Ala Ser Cys Asp Gln Cys Gln Leu Lys
 595 600 605

Gly Glu Ala Met His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
 610 615 620

Leu Ala Cys Thr His Leu Glu Gly Lys Ile Ile Leu Val Ala Val His
 625 630 635 640

Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
 645 650 655

Gln Glu Thr Ala Tyr Phe Ile Leu Lys Leu Ala Gly Arg Trp Pro Val
 660 665 670

Lys Val Ile His Thr Ala Asn Gly Ser Asn Phe Thr Ser Ala Ala Val
 675 680 685

Lys Ala Ala Cys Trp Trp Ala Gly Ile Gln Gln Glu Phe Gly Ile Pro
 690 695 700

Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys Glu Leu
 705 710 715 720

Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
 725 730 735

Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
 740 745 750

Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Ile Asp Ile Ile Ala Thr
 755 760 765

Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Ile Lys Ile Gln Asn
 770 775 780

Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asp Pro Ile Trp Lys Gly Pro
 785 790 795 800

Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
 805 810 815

Ser Asp Ile Lys Val Val Pro Arg Arg Lys Val Lys Ile Ile Lys Asp
 820 825 830

Tyr Gly Lys Gln Met Ala Gly Ala
 835 840

<210> 6

<211> 850

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos2Pol mosaic HIV antigen

<400> 6

Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro
 1 5 10 15

Gly Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys
 20 25 30

Ile Lys Ala Leu Val Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys
 35 40 45

Ile Ser Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala
 50 55 60

Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg
 65 70 75 80

Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile
 85 90 95

Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala
 100 105 110

Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys
 115 120 125

Tyr Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile
 130 135 140

Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala
 145 150 155 160

Ile Phe Gln Ser Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln
 165 170 175

Asn Pro Asp Ile Val Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly
 180 185 190

Ser Asp Leu Glu Ile Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg
 195 200 205

Gln His Leu Leu Arg Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln
 210 215 220

Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys
 225 230 235 240

Trp Thr Val Gln Pro Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val
 245 250 255

Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile
 260 265 270

Tyr Ala Gly Ile Lys Val Lys Gln Leu Cys Lys Leu Leu Arg Gly Thr
 275 280 285

Lys Ala Leu Thr Glu Val Val Pro Leu Thr Glu Glu Ala Glu Leu Glu
 290 295 300

Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr
 305 310 315 320

Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln
 325 330 335

Gly Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys
 340 345 350

Thr Gly Lys Tyr Ala Arg Met Arg Gly Ala His Thr Asn Asp Val Lys
 355 360 365

Gln Leu Thr Glu Ala Val Gln Lys Ile Ala Thr Glu Ser Ile Val Ile
 370 375 380

Trp Gly Lys Thr Pro Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp
 385 390 395 400

Glu Ala Trp Trp Thr Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp
 405 410 415

Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu
 420 425 430

Lys Glu Pro Ile Val Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala
 435 440 445

Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val Thr Asp Arg Gly
 450 455 460

Arg Gln Lys Val Val Ser Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala
 465 470 475 480

Leu Gln Ala Ile His Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn
 485 490 495

Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro
 500 505 510

Asp Lys Ser Glu Ser Glu Leu Val Ser Gln Ile Ile Glu Gln Leu Ile
 515 520 525

Lys Lys Glu Lys Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile
 530 535 540

Gly Gly Asn Glu Gln Val Asp Lys Leu Val Ser Arg Gly Ile Arg Lys
 545 550 555 560

Val Leu Phe Leu Asp Gly Ile Asp Lys Ala Gln Glu Glu His Glu Lys
 565 570 575

Tyr His Ser Asn Trp Arg Ala Met Ala Ser Glu Phe Asn Leu Pro Pro
 580 585 590

Ile Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu Lys
 595 600 605

Gly Glu Ala Ile His Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln
 610 615 620

Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val Ala Val His
 625 630 635 640

Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly
 645 650 655

Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala Gly Arg Trp Pro Val
 660 665 670

Lys Thr Ile His Thr Ala Asn Gly Ser Asn Phe Thr Ser Ala Thr Val
 675 680 685

Lys Ala Ala Cys Trp Trp Ala Gly Ile Lys Gln Glu Phe Gly Ile Pro
 690 695 700

Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Ile Asn Lys Glu Leu
 705 710 715 720

Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His Leu Lys Thr
 725 730 735

Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys Arg Lys Gly Gly
 740 745 750

Ile Gly Glu Tyr Ser Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Ser
 755 760 765

Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn
 770 775 780

Phe Arg Val Tyr Tyr Arg Asp Ser Arg Asp Pro Leu Trp Lys Gly Pro
 785 790 795 800

Ala Lys Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn
 805 810 815

Ser Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
 820 825 830

Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln Asp
 835 840 845

Glu Asp
 850

<210> 7

<211> 500

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos1Gag mosaic HIV antigen

<400> 7

Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg Trp
 1 5 10 15

Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Arg Leu Lys
 20 25 30

His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro
 35 40 45

Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Leu Gly Gln Leu
 50 55 60

Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn
 65 70 75 80

Thr Val Ala Thr Leu Tyr Cys Val His Gln Arg Ile Glu Ile Lys Asp
 85 90 95

Thr Lys Glu Ala Leu Glu Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys
 100 105 110

Lys Lys Ala Gln Gln Ala Ala Ala Asp Thr Gly Asn Ser Ser Gln Val
 115 120 125

Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile Gln Gly Gln Met Val His
 130 135 140

Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu
 145 150 155 160

Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser
 165 170 175

Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly
 180 185 190

Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu
 195 200 205

Ala Ala Glu Trp Asp Arg Val His Pro Val His Ala Gly Pro Ile Ala
 210 215 220

Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr
 225 230 235 240

Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile
 245 250 255

Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys
 260 265 270

Ile Val Arg Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly
 275 280 285

Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu
 290 295 300

Arg Ala Glu Gln Ala Ser Gln Asp Val Lys Asn Trp Met Thr Glu Thr
 305 310 315 320

Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala
 325 330 335

Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly
 340 345 350

Val Gly Gly Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser
 355 360 365

Gln Val Thr Asn Ser Ala Thr Ile Met Met Gln Arg Gly Asn Phe Arg
 370 375 380

Asn Gln Arg Lys Thr Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His
 385 390 395 400

Ile Ala Lys Asn Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys
 405 410 415

Gly Lys Glu Gly His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn
 420 425 430

Phe Leu Gly Lys Ile Trp Pro Ser Asn Lys Gly Arg Pro Gly Asn Phe
 435 440 445

Leu Gln Asn Arg Pro Glu Pro Thr Ala Pro Pro Glu Glu Ser Phe Arg
 450 455 460

Phe Gly Glu Glu Thr Thr Thr Pro Ser Gln Lys Gln Glu Pro Ile Asp
 465 470 475 480

Lys Glu Met Tyr Pro Leu Ala Ser Leu Lys Ser Leu Phe Gly Asn Asp
 485 490 495

Pro Ser Ser Gln
 500

<210> 8

<211> 491

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos2Gag mosaic HIV antigen

<400> 8

Met Gly Ala Arg Ala Ser Ile Leu Arg Gly Gly Lys Leu Asp Lys Trp
 1 5 10 15

Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys
 20 25 30

His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro
 35 40 45

Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Ile Lys Gln Leu
 50 55 60

Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Arg Ser Leu Phe Asn
 65 70 75 80

Thr Val Ala Thr Leu Tyr Cys Val His Ala Glu Ile Glu Val Arg Asp
 85 90 95

Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Gln
 100 105 110

Gln Lys Thr Gln Gln Ala Lys Glu Ala Asp Gly Lys Val Ser Gln Asn
 115 120 125

Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Pro Ile
 130 135 140

Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala
 145 150 155 160

Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala
 165 170 175

Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln
 180 185 190

Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu
 195 200 205

Trp Asp Arg Leu His Pro Val His Ala Gly Pro Val Ala Pro Gly Gln
 210 215 220

Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Asn Leu
 225 230 235 240

Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly
 245 250 255

Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg
 260 265 270

Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu
 275 280 285

Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu
 290 295 300

Gln Ala Thr Gln Asp Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val
 305 310 315 320

Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro
 325 330 335

Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly
 340 345 350

Pro Ser His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn
 355 360 365

Ser Thr Ile Leu Met Gln Arg Ser Asn Phe Lys Gly Ser Lys Arg Ile
 370 375 380

Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys
 385 390 395 400

Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His
 405 410 415

Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys Ile
 420 425 430

Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Ser Arg Pro
 435 440 445

Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr Thr
 450 455 460

Pro Ala Pro Lys Gln Glu Pro Lys Asp Arg Glu Pro Leu Thr Ser Leu
 465 470 475 480

Arg Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln
 485 490

<210> 9

<211> 1350

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos1GagPol mosaic HIV antigen

<400> 9

Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg Trp
 1 5 10 15

Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Arg Leu Lys
 20 25 30

His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro
 35 40 45

Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Leu Gly Gln Leu
 50 55 60

Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn
 65 70 75 80

Thr Val Ala Thr Leu Tyr Cys Val His Gln Arg Ile Glu Ile Lys Asp
 85 90 95

Thr Lys Glu Ala Leu Glu Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys
 100 105 110

Lys Lys Ala Gln Gln Ala Ala Ala Asp Thr Gly Asn Ser Ser Gln Val
 115 120 125

Ser Gln Asn Tyr Pro Ile Val Gln Asn Ile Gln Gly Gln Met Val His
130 135 140

Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val Glu
145 150 155 160

Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu Ser
165 170 175

Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly
180 185 190

Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu Glu
195 200 205

Ala Ala Glu Trp Asp Arg Val His Pro Val His Ala Gly Pro Ile Ala
210 215 220

Pro Gly Gln Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr
225 230 235 240

Ser Thr Leu Gln Glu Gln Ile Gly Trp Met Thr Asn Asn Pro Pro Ile
245 250 255

Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys
260 265 270

Ile Val Arg Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly
275 280 285

Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Thr Leu
290 295 300

Arg Ala Glu Gln Ala Ser Gln Asp Val Lys Asn Trp Met Thr Glu Thr
305 310 315 320

Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Lys Ala
 325 330 335

Leu Gly Pro Ala Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly
 340 345 350

Val Gly Gly Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser
 355 360 365

Gln Val Thr Asn Ser Ala Thr Ile Met Met Gln Arg Gly Asn Phe Arg
 370 375 380

Asn Gln Arg Lys Thr Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His
 385 390 395 400

Ile Ala Lys Asn Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys
 405 410 415

Gly Lys Glu Gly His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn
 420 425 430

Phe Leu Gly Lys Ile Trp Pro Ser Asn Lys Gly Arg Pro Gly Asn Phe
 435 440 445

Leu Gln Asn Arg Pro Glu Pro Thr Ala Pro Pro Glu Glu Ser Phe Arg
 450 455 460

Phe Gly Glu Glu Thr Thr Thr Pro Ser Gln Lys Gln Glu Pro Ile Asp
 465 470 475 480

Lys Glu Met Tyr Pro Leu Ala Ser Leu Lys Ser Leu Phe Gly Asn Asp
 485 490 495

Pro Ser Ser Gln Met Ala Pro Ile Ser Pro Ile Glu Thr Val Pro Val
 500 505 510

Lys Leu Lys Pro Gly Met Asp Gly Pro Arg Val Lys Gln Trp Pro Leu
 515 520 525

Thr Glu Glu Lys Ile Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu
530 535 540

Lys Glu Gly Lys Ile Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr
545 550 555 560

Pro Val Phe Ala Ile Lys Lys Lys Asp Ser Thr Lys Trp Arg Lys Leu
565 570 575

Val Asp Phe Arg Glu Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val
580 585 590

Gln Leu Gly Ile Pro His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val
595 600 605

Thr Val Leu Ala Val Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu
610 615 620

Gly Phe Arg Lys Tyr Thr Ala Phe Thr Ile Pro Ser Thr Asn Asn Glu
625 630 635 640

Thr Pro Gly Ile Arg Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys
645 650 655

Gly Ser Pro Ala Ile Phe Gln Cys Ser Met Thr Arg Ile Leu Glu Pro
660 665 670

Phe Arg Ala Lys Asn Pro Glu Ile Val Ile Tyr Gln Tyr Met Ala Ala
675 680 685

Leu Tyr Val Gly Ser Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile
690 695 700

Glu Glu Leu Arg Glu His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp
705 710 715 720

Lys Lys His Gln Lys Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu
 725 730 735

His Pro Asp Lys Trp Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp
 740 745 750

Ser Trp Thr Val Asn Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp
 755 760 765

Ala Ser Gln Ile Tyr Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu
 770 775 780

Leu Arg Gly Ala Lys Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu
 785 790 795 800

Ala Glu Leu Glu Leu Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val
 805 810 815

His Gly Val Tyr Tyr Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln
 820 825 830

Lys Gln Gly His Asp Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe
 835 840 845

Lys Asn Leu Lys Thr Gly Lys Tyr Ala Lys Met Arg Thr Ala His Thr
 850 855 860

Asn Asp Val Lys Gln Leu Thr Glu Ala Val Gln Lys Ile Ala Met Glu
 865 870 875 880

Ser Ile Val Ile Trp Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln
 885 890 895

Lys Glu Thr Trp Glu Thr Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp
 900 905 910

Ile Pro Glu Trp Glu Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp
 915 920 925

Tyr Gln Leu Glu Lys Asp Pro Ile Ala Gly Val Glu Thr Phe Tyr Val
 930 935 940

Ala Gly Ala Ala Asn Arg Glu Thr Lys Leu Gly Lys Ala Gly Tyr Val
 945 950 955 960

Thr Asp Arg Gly Arg Gln Lys Ile Val Ser Leu Thr Glu Thr Thr Asn
 965 970 975

Gln Lys Thr Ala Leu Gln Ala Ile Tyr Leu Ala Leu Gln Asp Ser Gly
 980 985 990

Ser Glu Val Asn Ile Val Thr Ala Ser Gln Tyr Ala Leu Gly Ile Ile
 995 1000 1005

Gln Ala Gln Pro Asp Lys Ser Glu Ser Glu Leu Val Asn Gln Ile
 1010 1015 1020

Ile Glu Gln Leu Ile Lys Lys Glu Arg Val Tyr Leu Ser Trp Val
 1025 1030 1035

Pro Ala His Lys Gly Ile Gly Gly Asn Glu Gln Val Asp Lys Leu
 1040 1045 1050

Val Ser Ser Gly Ile Arg Lys Val Leu Phe Leu Asp Gly Ile Asp
 1055 1060 1065

Lys Ala Gln Glu Glu His Glu Lys Tyr His Ser Asn Trp Arg Ala
 1070 1075 1080

Met Ala Ser Asp Phe Asn Leu Pro Pro Val Val Ala Lys Glu Ile
 1085 1090 1095

Val Ala Ser Cys Asp Gln Cys Gln Leu Lys Gly Glu Ala Met His
 1100 1105 1110

Gly Gln Val Asp Cys Ser Pro Gly Ile Trp Gln Leu Ala Cys Thr
 1115 1120 1125

His Leu Glu Gly Lys Ile Ile Leu Val Ala Val His Val Ala Ser
 1130 1135 1140

Gly Tyr Ile Glu Ala Glu Val Ile Pro Ala Glu Thr Gly Gln Glu
 1145 1150 1155

Thr Ala Tyr Phe Ile Leu Lys Leu Ala Gly Arg Trp Pro Val Lys
 1160 1165 1170

Val Ile His Thr Ala Asn Gly Ser Asn Phe Thr Ser Ala Ala Val
 1175 1180 1185

Lys Ala Ala Cys Trp Trp Ala Gly Ile Gln Gln Glu Phe Gly Ile
 1190 1195 1200

Pro Tyr Asn Pro Gln Ser Gln Gly Val Val Ala Ser Met Asn Lys
 1205 1210 1215

Glu Leu Lys Lys Ile Ile Gly Gln Val Arg Asp Gln Ala Glu His
 1220 1225 1230

Leu Lys Thr Ala Val Gln Met Ala Val Phe Ile His Asn Phe Lys
 1235 1240 1245

Arg Lys Gly Gly Ile Gly Gly Tyr Ser Ala Gly Glu Arg Ile Ile
 1250 1255 1260

Asp Ile Ile Ala Thr Asp Ile Gln Thr Lys Glu Leu Gln Lys Gln
 1265 1270 1275

Ile Ile Lys Ile Gln Asn Phe Arg Val Tyr Tyr Arg Asp Ser Arg
 1280 1285 1290

Asp Pro Ile Trp Lys Gly Pro Ala Lys Leu Leu Trp Lys Gly Glu
 1295 1300 1305

Gly Ala Val Val Ile Gln Asp Asn Ser Asp Ile Lys Val Val Pro
 1310 1315 1320

Arg Arg Lys Val Lys Ile Ile Lys Asp Tyr Gly Lys Gln Met Ala
 1325 1330 1335

Gly Ala Asp Cys Val Ala Gly Arg Gln Asp Glu Asp
 1340 1345 1350

<210> 10

<211> 1341

<212> PRT

<213> Artificial Sequence

<220>

<223> Mos2GagPol mosaic HIV antigen

<400> 10

Met Gly Ala Arg Ala Ser Ile Leu Arg Gly Gly Lys Leu Asp Lys Trp
 1 5 10 15

Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys
 20 25 30

His Leu Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro
 35 40 45

Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Ile Lys Gln Leu
 50 55 60

Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Arg Ser Leu Phe Asn
 65 70 75 80

Thr Val Ala Thr Leu Tyr Cys Val His Ala Glu Ile Glu Val Arg Asp
 85 90 95

Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Gln
 100 105 110

Gln Lys Thr Gln Gln Ala Lys Glu Ala Asp Gly Lys Val Ser Gln Asn
 115 120 125

Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Pro Ile
 130 135 140

Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala
 145 150 155 160

Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala
 165 170 175

Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln
 180 185 190

Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu
 195 200 205

Trp Asp Arg Leu His Pro Val His Ala Gly Pro Val Ala Pro Gly Gln
 210 215 220

Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Asn Leu
 225 230 235 240

Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly
 245 250 255

Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg
 260 265 270

Met Tyr Ser Pro Thr Ser Ile Leu Asp Ile Lys Gln Gly Pro Lys Glu
 275 280 285

Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu
 290 295 300

Gln Ala Thr Gln Asp Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val
 305 310 315 320

Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro
 325 330 335

Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly
 340 345 350

Pro Ser His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn
 355 360 365

Ser Thr Ile Leu Met Gln Arg Ser Asn Phe Lys Gly Ser Lys Arg Ile
 370 375 380

Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn Cys
 385 390 395 400

Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly His
 405 410 415

Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys Ile
 420 425 430

Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Ser Arg Pro
 435 440 445

Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr Thr
 450 455 460

Pro Ala Pro Lys Gln Glu Pro Lys Asp Arg Glu Pro Leu Thr Ser Leu
 465 470 475 480

Arg Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln Met Ala Pro Ile Ser
 485 490 495

Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly Met Asp Gly Pro
 500 505 510

Lys Val Lys Gln Trp Pro Leu Thr Glu Glu Lys Ile Lys Ala Leu Val
515 520 525

Glu Ile Cys Thr Glu Met Glu Lys Glu Gly Lys Ile Ser Lys Ile Gly
530 535 540

Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala Ile Lys Lys Lys Asp
545 550 555 560

Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu Leu Asn Lys Arg
565 570 575

Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro His Pro Ala Gly
580 585 590

Leu Lys Lys Lys Lys Ser Val Thr Val Leu Ala Val Gly Asp Ala Tyr
595 600 605

Phe Ser Val Pro Leu Asp Glu Asp Phe Arg Lys Tyr Thr Ala Phe Thr
610 615 620

Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg Tyr Gln Tyr Asn
625 630 635 640

Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile Phe Gln Ser Ser
645 650 655

Met Thr Lys Ile Leu Glu Pro Phe Arg Lys Gln Asn Pro Asp Ile Val
660 665 670

Ile Tyr Gln Tyr Met Ala Ala Leu Tyr Val Gly Ser Asp Leu Glu Ile
675 680 685

Gly Gln His Arg Thr Lys Ile Glu Glu Leu Arg Gln His Leu Leu Arg
690 695 700

Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln Lys Glu Pro Pro Phe
705 710 715 720

Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp Thr Val Gln Pro
725 730 735

Ile Val Leu Pro Glu Lys Asp Ser Trp Thr Val Asn Asp Ile Gln Lys
740 745 750

Leu Val Gly Lys Leu Asn Trp Ala Ser Gln Ile Tyr Ala Gly Ile Lys
755 760 765

Val Lys Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys Ala Leu Thr Glu
770 775 780

Val Val Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu Ala Glu Asn Arg
785 790 795 800

Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr Asp Pro Ser Lys
805 810 815

Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Gln Gly Gln Trp Thr Tyr
820 825 830

Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr Gly Lys Tyr Ala
835 840 845

Arg Met Arg Gly Ala His Thr Asn Asp Val Lys Gln Leu Thr Glu Ala
850 855 860

Val Gln Lys Ile Ala Thr Glu Ser Ile Val Ile Trp Gly Lys Thr Pro
865 870 875 880

Lys Phe Lys Leu Pro Ile Gln Lys Glu Thr Trp Glu Ala Trp Trp Thr
885 890 895

Glu Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu Phe Val Asn Thr
900 905 910

Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys Glu Pro Ile Val
 915 920 925

Gly Ala Glu Thr Phe Tyr Val Ala Gly Ala Ala Asn Arg Glu Thr Lys
 930 935 940

Leu Gly Lys Ala Gly Tyr Val Thr Asp Arg Gly Arg Gln Lys Val Val
 945 950 955 960

Ser Leu Thr Asp Thr Thr Asn Gln Lys Thr Ala Leu Gln Ala Ile His
 965 970 975

Leu Ala Leu Gln Asp Ser Gly Leu Glu Val Asn Ile Val Thr Ala Ser
 980 985 990

Gln Tyr Ala Leu Gly Ile Ile Gln Ala Gln Pro Asp Lys Ser Glu Ser
 995 1000 1005

Glu Leu Val Ser Gln Ile Ile Glu Gln Leu Ile Lys Lys Glu Lys
 1010 1015 1020

Val Tyr Leu Ala Trp Val Pro Ala His Lys Gly Ile Gly Gly Asn
 1025 1030 1035

Glu Gln Val Asp Lys Leu Val Ser Arg Gly Ile Arg Lys Val Leu
 1040 1045 1050

Phe Leu Asp Gly Ile Asp Lys Ala Gln Glu Glu His Glu Lys Tyr
 1055 1060 1065

His Ser Asn Trp Arg Ala Met Ala Ser Glu Phe Asn Leu Pro Pro
 1070 1075 1080

Ile Val Ala Lys Glu Ile Val Ala Ser Cys Asp Lys Cys Gln Leu
 1085 1090 1095

Lys Gly Glu Ala Ile His Gly Gln Val Asp Cys Ser Pro Gly Ile
 1100 1105 1110

Trp Gln Leu Ala Cys Thr His Leu Glu Gly Lys Val Ile Leu Val
 1115 1120 1125

Ala Val His Val Ala Ser Gly Tyr Ile Glu Ala Glu Val Ile Pro
 1130 1135 1140

Ala Glu Thr Gly Gln Glu Thr Ala Tyr Phe Leu Leu Lys Leu Ala
 1145 1150 1155

Gly Arg Trp Pro Val Lys Thr Ile His Thr Ala Asn Gly Ser Asn
 1160 1165 1170

Phe Thr Ser Ala Thr Val Lys Ala Ala Cys Trp Trp Ala Gly Ile
 1175 1180 1185

Lys Gln Glu Phe Gly Ile Pro Tyr Asn Pro Gln Ser Gln Gly Val
 1190 1195 1200

Val Ala Ser Ile Asn Lys Glu Leu Lys Lys Ile Ile Gly Gln Val
 1205 1210 1215

Arg Asp Gln Ala Glu His Leu Lys Thr Ala Val Gln Met Ala Val
 1220 1225 1230

Phe Ile His Asn Phe Lys Arg Lys Gly Gly Ile Gly Glu Tyr Ser
 1235 1240 1245

Ala Gly Glu Arg Ile Val Asp Ile Ile Ala Ser Asp Ile Gln Thr
 1250 1255 1260

Lys Glu Leu Gln Lys Gln Ile Thr Lys Ile Gln Asn Phe Arg Val
 1265 1270 1275

Tyr Tyr Arg Asp Ser Arg Asp Pro Leu Trp Lys Gly Pro Ala Lys
 1280 1285 1290

Leu Leu Trp Lys Gly Glu Gly Ala Val Val Ile Gln Asp Asn Ser
 1295 1300 1305

Asp Ile Lys Val Val Pro Arg Arg Lys Ala Lys Ile Ile Arg Asp
 1310 1315 1320

Tyr Gly Lys Gln Met Ala Gly Asp Asp Cys Val Ala Ser Arg Gln
 1325 1330 1335

Asp Glu Asp
 1340

<210> 11
 <211> 625
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mos1SEnv synthetic HIV envelope protein

<400> 11

Met Gly Asn Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys
 1 5 10 15

Asp Ala Lys Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Glu
 20 25 30

Lys Glu Val His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp
 35 40 45

Pro Asn Pro Gln Glu Ile Val Leu Gly Asn Val Thr Glu Asn Phe Asn
 50 55 60

Met Trp Lys Asn Asp Met Val Asp Gln Met His Glu Asp Ile Ile Ser
 65 70 75 80

Leu Trp Asp Ala Ser Leu Glu Pro Cys Val Lys Leu Thr Pro Leu Cys
 85 90 95

Val Thr Leu Asn Cys Arg Asn Val Arg Asn Val Ser Ser Asn Gly Thr
 100 105 110

Tyr Asn Ile Ile His Asn Glu Thr Tyr Lys Glu Met Lys Asn Cys Ser
 115 120 125

Phe Asn Ala Thr Thr Val Val Glu Asp Arg Lys Gln Lys Val His Ala
 130 135 140

Leu Phe Tyr Arg Leu Asp Ile Val Pro Leu Asp Glu Asn Asn Ser Ser
 145 150 155 160

Glu Lys Ser Ser Glu Asn Ser Ser Glu Tyr Tyr Arg Leu Ile Asn Cys
 165 170 175

Asn Thr Ser Ala Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Asp Pro
 180 185 190

Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys
 195 200 205

Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser Thr
 210 215 220

Val Gln Cys Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu Leu
 225 230 235 240

Leu Asn Gly Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu Asn
 245 250 255

Leu Thr Asn Asn Ala Lys Thr Ile Ile Val His Leu Asn Glu Thr Val
 260 265 270

Asn Ile Thr Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg
 275 280 285

Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp
 290 295 300

Ile Arg Gln Ala His Cys Asn Leu Ser Arg Asp Gly Trp Asn Lys Thr
 305 310 315 320

Leu Gln Gly Val Lys Lys Lys Leu Ala Glu His Phe Pro Asn Lys Thr
 325 330 335

Ile Lys Phe Ala Pro His Ser Gly Gly Asp Leu Glu Ile Thr Thr His
 340 345 350

Thr Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Asn Leu
 355 360 365

Phe Asn Glu Ser Asn Ile Glu Arg Asn Asp Ser Ile Ile Thr Leu Pro
 370 375 380

Cys Arg Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Arg Ala
 385 390 395 400

Ile Tyr Ala Pro Pro Ile Ala Gly Asn Ile Thr Cys Arg Ser Asn Ile
 405 410 415

Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Ser Asn Asn Gly Val Pro
 420 425 430

Asn Asp Thr Glu Thr Phe Arg Pro Gly Gly Gly Asp Met Arg Asn Asn
 435 440 445

Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Glu Val Lys Pro Leu
 450 455 460

Gly Val Ala Pro Thr Glu Ala Lys Arg Arg Val Val Glu Arg Glu Lys
 465 470 475 480

Arg Ala Val Gly Ile Gly Ala Val Phe Leu Gly Ile Leu Gly Ala Ala
 485 490 495

Gly Ser Thr Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg
 500 505 510

Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala
 515 520 525

Ile Glu Ala Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys
 530 535 540

Gln Leu Gln Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu Gln Asp Gln
 545 550 555 560

Gln Leu Leu Gly Leu Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr
 565 570 575

Ala Val Pro Trp Asn Thr Ser Trp Ser Asn Lys Ser Gln Thr Asp Ile
 580 585 590

Trp Asp Asn Met Thr Trp Met Gln Trp Asp Lys Glu Ile Gly Asn Tyr
 595 600 605

Thr Gly Glu Ile Tyr Arg Leu Leu Glu Glu Ser Gln Asn Gln Gln Glu
 610 615 620

Lys
 625

<210> 12
 <211> 711
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Mos2SEnv synthetic HIV envelope protein

<400> 12

Met Arg Val Arg Gly Met Leu Arg Asn Trp Gln Gln Trp Trp Ile Trp
 1 5 10 15

Ser Ser Leu Gly Phe Trp Met Leu Met Ile Tyr Ser Val Met Gly Asn
 20 25 30

Leu Trp Val Thr Val Tyr Tyr Gly Val Pro Val Trp Lys Asp Ala Lys
 35 40 45

Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Glu Lys Glu Val
 50 55 60

His Asn Val Trp Ala Thr His Ala Cys Val Pro Thr Asp Pro Asn Pro
 65 70 75 80

Gln Glu Ile Val Leu Gly Asn Val Thr Glu Asn Phe Asn Met Trp Lys
 85 90 95

Asn Asp Met Val Asp Gln Met His Glu Asp Ile Ile Ser Leu Trp Asp
 100 105 110

Ala Ser Leu Glu Pro Cys Val Lys Leu Thr Pro Leu Cys Val Thr Leu
 115 120 125

Asn Cys Arg Asn Val Arg Asn Val Ser Ser Asn Gly Thr Tyr Asn Ile
 130 135 140

Ile His Asn Glu Thr Tyr Lys Glu Met Lys Asn Cys Ser Phe Asn Ala
 145 150 155 160

Thr Thr Val Val Glu Asp Arg Lys Gln Lys Val His Ala Leu Phe Tyr
 165 170 175

Arg Leu Asp Ile Val Pro Leu Asp Glu Asn Asn Ser Ser Glu Lys Ser
 180 185 190

Ser Glu Asn Ser Ser Glu Tyr Tyr Arg Leu Ile Asn Cys Asn Thr Ser
 195 200 205

Ala Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Asp Pro Ile Pro Ile
 210 215 220

His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys Asn Asn Lys
 225 230 235 240

Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser Thr Val Gln Cys
 245 250 255

Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly
 260 265 270

Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu Asn Leu Thr Asn
 275 280 285

Asn Ala Lys Thr Ile Ile Val His Leu Asn Glu Thr Val Asn Ile Thr
 290 295 300

Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gly Pro
 305 310 315 320

Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg Gln
 325 330 335

Ala His Cys Asn Leu Ser Arg Asp Gly Trp Asn Lys Thr Leu Gln Gly
 340 345 350

Val Lys Lys Lys Leu Ala Glu His Phe Pro Asn Lys Thr Ile Lys Phe
 355 360 365

Ala Pro His Ser Gly Gly Asp Leu Glu Ile Thr Thr His Thr Phe Asn
 370 375 380

Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Asn Leu Phe Asn Glu
 385 390 395 400

Ser Asn Ile Glu Arg Asn Asp Ser Ile Ile Thr Leu Pro Cys Arg Ile
 405 410 415

Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Arg Ala Ile Tyr Ala
 420 425 430

Pro Pro Ile Ala Gly Asn Ile Thr Cys Arg Ser Asn Ile Thr Gly Leu
 435 440 445

Leu Leu Thr Arg Asp Gly Gly Ser Asn Asn Gly Val Pro Asn Asp Thr
 450 455 460

Glu Thr Phe Arg Pro Gly Gly Gly Asp Met Arg Asn Asn Trp Arg Ser
 465 470 475 480

Glu Leu Tyr Lys Tyr Lys Val Val Glu Val Lys Pro Leu Gly Val Ala
 485 490 495

Pro Thr Glu Ala Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val
 500 505 510

Gly Ile Gly Ala Val Phe Leu Gly Ile Leu Gly Ala Ala Gly Ser Thr
 515 520 525

Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu
 530 535 540

Ser Gly Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala
 545 550 555 560

Gln Gln His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln
 565 570 575

Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu Gln Asp Gln Gln Leu Leu
 580 585 590

Gly Leu Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val Pro
 595 600 605

Trp Asn Thr Ser Trp Ser Asn Lys Ser Gln Thr Asp Ile Trp Asp Asn
 610 615 620

Met Thr Trp Met Gln Trp Asp Lys Glu Ile Gly Asn Tyr Thr Gly Glu
 625 630 635 640

Ile Tyr Arg Leu Leu Glu Glu Ser Gln Asn Gln Gln Glu Lys Asn Glu
 645 650 655

Lys Asp Leu Leu Ala Leu Asp Ser Trp Asn Asn Leu Trp Asn Trp Phe
 660 665 670

Ser Ile Ser Lys Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val
 675 680 685

Gly Gly Leu Ile Gly Leu Arg Ile Ile Phe Ala Val Leu Ser Ile Val
 690 695 700

Asn Arg Val Arg Gln Gly Tyr
 705 710

<210> 13
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> T4-fibrin "foldon" trimerization domain

<400> 13

Gly Ser Gly Gly Tyr Ile Pro Glu Ala Pro Arg Asp Gly Gln Ala Tyr
 1 5 10 15

Val Arg Lys Asp Gly Glu Trp Val Leu Leu Ser Thr Phe Leu
 20 25 30

<210> 14
 <211> 32
 <212> PRT
 <213> Artificial Sequence

<220>

<223> coiled-coil trimerization domain derived from GCN4

<400> 14

Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr
1 5 10 15

His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Val
 20 25 30

ABSTRACT

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described
5 immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered
10 alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

Planche de l'abrégé

FIG 1A




FIG 1B

